


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:59Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406192" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406192</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="d183597971" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406192</article-id><article-id pub-id-type="pmcid-ver">PMC12406192.1</article-id><article-id pub-id-type="pmcaid">12406192</article-id><article-id pub-id-type="pmcaiid">12406192</article-id><article-id pub-id-type="pmid">40815386</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c00750</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sustainable Joulli&#233;&#8211;Ugi
and Continuous
Flow Implementation Led to Novel Captopril-Inspired Broad-Spectrum
Metallo-&#946;-Lactamase Inhibitors</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e19-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6499883</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0908-037X</contrib-id><name name-style="western"><surname>Alfano</surname><given-names initials="AI">Antonella Ilenia</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2364956</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5526-5554</contrib-id><name name-style="western"><surname>Pelliccia</surname><given-names initials="S">Sveva</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7088600</contrib-id><name name-style="western"><surname>Barone</surname><given-names initials="S">Simona</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6873858</contrib-id><name name-style="western"><surname>Cutarella</surname><given-names initials="L">Luigi</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7556594</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0000-8315-3499</contrib-id><name name-style="western"><surname>Cancade</surname><given-names initials="SMI">Sacha Mich&#232;le Idriss</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557843</contrib-id><name name-style="western"><surname>Baia</surname><given-names initials="V">Valerio</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557846</contrib-id><name name-style="western"><surname>Cassese</surname><given-names initials="E">Emilia</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557848</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0236-1200</contrib-id><name name-style="western"><surname>Russomanno</surname><given-names initials="P">Pasquale</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7475170</contrib-id><name name-style="western"><surname>Messano</surname><given-names initials="N">Nicol&#242;</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557856</contrib-id><name name-style="western"><surname>Frank</surname><given-names initials="D">Denia</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1032429</contrib-id><name name-style="western"><surname>Weizel</surname><given-names initials="L">Lilia</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath12" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557857</contrib-id><name name-style="western"><surname>Rotter</surname><given-names initials="MJ">Marco J.</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath13" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557861</contrib-id><name name-style="western"><surname>Brunst</surname><given-names initials="S">Steffen</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath14" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5079470</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4029-2955</contrib-id><name name-style="western"><surname>Wichelhaus</surname><given-names initials="TA">Thomas A.</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath15" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7557862</contrib-id><name name-style="western"><surname>Proschak</surname><given-names initials="E">Ewgenij</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath16" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1881297</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2585-7791</contrib-id><name name-style="western"><surname>Tedesco</surname><given-names initials="D">Daniele</given-names></name><xref rid="aff7" ref-type="aff"/></contrib><contrib id="ath17" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1754126</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2398-1254</contrib-id><name name-style="western"><surname>Mori</surname><given-names initials="M">Mattia</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath18" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">761092</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9483-4476</contrib-id><name name-style="western"><surname>Docquier</surname><given-names initials="JD">Jean Denis</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath19" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1886806</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6288-2681</contrib-id><name name-style="western"><surname>Summa</surname><given-names initials="V">Vincenzo</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath20" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2435239</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9119-3773</contrib-id><name name-style="western"><surname>Brindisi</surname><given-names initials="M">Margherita</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Pharmacy (Department of Excellence 2023-2027)</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9307</institution-id><institution>University of Naples Federico II</institution></institution-wrap>, <addr-line>Via D. Montesano 49</addr-line>, <postal-code>80131</postal-code>
<city>Naples</city>, <country country="IT">Italy</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Department
of Biotechnology, Chemistry and Pharmacy</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9313</institution-id><institution>University of Siena</institution></institution-wrap>, <addr-line>Via Aldo Moro 2</addr-line>, <postal-code>53100</postal-code>
<city>Siena</city>, <country country="IT">Italy</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Department
of Medical Biotechnologies</institution>, <institution>University of
Siena</institution>, <addr-line>Viale Bracci 16</addr-line>, <postal-code>53100</postal-code>
<city>Siena</city>, <country country="IT">Italy</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Magnetic
Resonance Centre (CERM), Consorzio Interuniversitario Risonanze Magnetiche
di Metallo Proteine (CIRMMP) and Department of Chemistry &#8220;Ugo
Schiff&#8221;</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9300</institution-id><institution>University of Florence</institution></institution-wrap>, <addr-line>Via L. Sacconi 6</addr-line>, <postal-code>50019</postal-code>
<city>Sesto Fiorentino</city>, <country country="IT">Italy</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9173</institution-id><institution>Goethe
University Frankfurt</institution></institution-wrap>, <institution content-type="dept">University Hospital,
Institute of Medical Microbiology and Infection Control</institution>, <addr-line>Paul-Ehrlich-Str. 40</addr-line>, <postal-code>60596</postal-code>
<city>Frankfurt am Main</city>, <country country="DE">Germany</country>
</aff><aff id="aff6">
<label>#</label>
<institution content-type="dept">Institute
of Pharmaceutical Chemistry</institution>, <institution>Goethe-University
of Frankfurt</institution>, <addr-line>Max-von-Laue
Str. 9</addr-line>, <postal-code>D-60438</postal-code>
<city>Frankfurt am Main</city>, <country country="DE">Germany</country>
</aff><aff id="aff7">
<label>&#8711;</label>
<institution>Institute
for Organic Synthesis and Photoreactivity (ISOF), National Research
Council of Italy (CNR)</institution>, <addr-line>Via P. Gobetti 101</addr-line>, <postal-code>40129</postal-code>
<city>Bologna</city>, <country country="IT">Italy</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>margherita.brindisi@unina.it</email>. Tel. <phone>+39081678710</phone>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17236</fpage><lpage>17257</lpage><history><date date-type="received"><day>14</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>7</month><year>2025</year></date><date date-type="online"><day>15</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-15"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-15">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c00750.pdf"/><abstract><p>Metallo-&#946;-lactamases
(MBL) production is one of the most
alarming bacterial resistance mechanisms, conferring broad-spectrum
resistance to most &#946;-lactam antibiotics and combinations with
&#946;-lactamase inhibitors. Since no MBL inhibitors have been approved
yet, the quest for novel, safe, and effective compounds, possibly
endowed with broad-spectrum activity against clinically relevant MBLs,
represents an urgent clinical need. Inspired by captopril, which behaves
as a weak MBL inhibitor, we herein report a continuous flow protocol
for the generation of new MBL inhibitors. We employed a Joulli&#233;&#8211;Ugi
multicomponent reaction for generating two indoline-based subseries,
reproducing the captopril binding mode, while increasing the hydrophobic
interactions within the MBL active site. Interaction between inhibitors
and five clinically relevant MBL isoforms (NDM-1, VIM-1, VIM-2, IMP-1,
and IMP-7) was investigated by biochemical methods and rationalized
through docking studies. Furthermore, the activity in clinical isolates
in synergy with &#946;-lactam antibiotics was assessed, thus paving
the way to a further optimization campaign.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c00750_0018.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c00750_0016.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Ministero dell'Universit&#224; e della Ricerca</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100021856</institution-id></institution-wrap></funding-source><award-id>CN00000041</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Ministero dell'Universit&#224; e della Ricerca</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100021856</institution-id></institution-wrap></funding-source><award-id>CUP_B63C22001400007</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>Ministero dell'Universit&#224; e della Ricerca</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100021856</institution-id></institution-wrap></funding-source><award-id>PE00000007</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c00750</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c00750</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>d7eccc60642473b3f12d7484a66aaeb7edb12e98529ec5db39e5b0e02d55c011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Antimicrobial resistance
(AMR) can be seen as a slow pandemic posing
a huge threat to public health worldwide. &#946;-Lactam antibiotics,
including penicillins, cephalosporins, and more importantly the life-saving
carbapenems, are the cornerstones of antimicrobial chemotherapy and
still represent extremely valuable antibacterial drugs, although their
efficacy is steadily declining.<xref rid="ref1" ref-type="bibr"/> Several
clinically relevant Gram-negative (diderm) pathogens (carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter
baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Enterobacter spp</italic>.)&#58872;included among the
acronymically dubbed &#8216;ESKAPE pathogens&#8217;&#8217;&#58872;have
become highly resistant to the vast majority of available antibacterial
drugs and are able to dodge the biocidal action of antibiotics.<named-content content-type="bibref-group">
<xref rid="ref2" ref-type="bibr"/>&#8722;<xref rid="ref3" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref4" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr"/>
</named-content> Regrettably, the situation is not expected to improve since current
estimates predict that AMR, already accounting for over 1.2 million
deaths globally, could represent the main cause of death in 2050 (10
million deaths per year), threatening the outcome of even the simplest
medical procedure.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>&#8722;<xref rid="ref8" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref9" ref-type="bibr"/>
</named-content> The COVID-19 pandemic further aggravated this scenario,
since COVID-19 patients are routinely treated with broad-spectrum
antibiotics, including expanded-spectrum cephalosporins (e.g., ceftriaxone,
ceftazidime, and cefepime), quinolones, and carbapenems.<xref rid="ref10" ref-type="bibr"/> Notably, infections with antibiotic-resistant <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">P. aeruginosa</italic>, or <italic toggle="yes">A. baumannii</italic> have been reported in patients with
COVID-19 in intensive care units. The advent of mobilized colistin
resistance-1 in 2015,<xref rid="ref11" ref-type="bibr"/> and transferable
tigecycline resistance genes in 2019,<xref rid="ref12" ref-type="bibr"/> which mediate resistance to colistin and tigecycline, respectively,
means that the efficacy of all clinically vital antibiotics for serious
Gram-negative infections is compromised, with cefiderocol being a
last-resort backup antibiotic. Regrettably, these circumstances create
a so-called perfect storm for an accelerated evolution of antimicrobial
resistance.<xref rid="ref13" ref-type="bibr"/>
</p><p>Resistance to carbapenems
among Gram-negative bacteria is primarily
due to the production of one or more carbapenemase(s), which inactivate
these life-saving drugs. These enzymes are frequently encoded by plasmids
that are easily transferred among strains. Bacteria achieve these
challenging chemical reactions with two families of hydrolytic enzymes:
serine &#946;-lactamases (SBLs) using a catalytic conserved serine
residue and metallo-&#946;-lactamases (MBLs) using one or two zinc
ions for catalysis. The increased prevalence of serine-carbapenemases
and MBLs makes &#946;-lactam antibiotics increasingly ineffective
for the treatment of infections caused by Multidrug-resistant/extensively
drug-resistant (MDR/XDR) Gram-negative isolates.<xref rid="ref14" ref-type="bibr"/>
</p><p>MBLs are of particular interest and concern given
several factors:
(i) their ability to hydrolyze and provide resistance to virtually
all &#946;-lactam antibiotics (except monobactams); (ii) the unavailability
of clinically useful MBL inhibitors; (iii) the rapid pace at which
new variants are isolated; (iv) the transferability of their encoding
genes, and (v) their ubiquity, since they have been identified in
both nosocomial and environmental strains.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content>
</p><p>MBLs belong to three subclasses (B1, B2, and B3), based primarily
on their metal content and different active site features. The &#946;-lactamase
genes encoding subclass B1MBL are largely plasmid-borne and are of
greater clinical relevance compared with those of subclass B2 and
B3 enzymes. Imipenemase (IMP), Verona Integron-encoded Metallo-carbapenemase
(VIM), and New Delhi Metallo-&#946;-lactamase (NDM) subtypes are
the three most common MBLs found in clinical isolates and belong to
subclass B1.<xref rid="ref17" ref-type="bibr"/> Notably, NDM-type enzymes
are currently the predominant MBLs in Europe.<xref rid="ref18" ref-type="bibr"/> NDM-producing microorganisms can cause life-threatening infections;
therefore, the fact that these microorganisms are actively disseminating
outside the healthcare system is a matter of concern.</p><p>Eight
compounds have been approved over the years as SBL inhibitors
to be used in different combinations with antibiotics, with enmetazobactam
and durlobactam being the last addition to the armamentarium.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref20" ref-type="bibr"/>
</named-content> However, none of these inhibitors show activity against the MBL-producing
strains. Combinations with MBL inhibitors are currently unavailable
for clinical use; therefore, the development of broad-spectrum MBL
inhibitors able to restore the efficacy of existing antibiotics represents
an extremely urgent medical need.<named-content content-type="bibref-group">
<xref rid="ref21" ref-type="bibr"/>&#8722;<xref rid="ref22" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr"/>
</named-content>
</p><p>Although diverse chemical
templates have been lately proposed as
MBL inhibitors, poor sequence similarity among various members, selectivity
issues toward human metalloenzymes, and the presence of shallow active
sites pose a relevant hurdle to the development of safe and effective
broad-spectrum MBL inhibitors.<named-content content-type="bibref-group">
<xref rid="ref25" ref-type="bibr"/>&#8722;<xref rid="ref26" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref27" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref28" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref29" ref-type="bibr"/>
</named-content> In this context, it is worth mentioning taniborbactam, a pan-spectrum
bicyclic boronate inhibitor, developed in combination with cefepime,
which completed phase 3 clinical trials in 2022,<xref rid="ref30" ref-type="bibr"/> and xeruborbactam (QPX7728), an orally available inhibitor
featuring a similar scaffold which completed phase 1 clinical trials
in combination with the &#946;-lactam QPX2014.<xref rid="ref31" ref-type="bibr"/>
</p><p>As per established drug discovery practice, besides <italic toggle="yes">de
novo</italic> design of novel chemical entities behaving as MBL inhibitors,
approved drugs were also engaged for their inhibitory potential toward
these metalloenzymes. Accordingly, as shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>, <sc>l</sc>-captopril (<bold>1</bold>) and <sc>d</sc>-captopril (<bold>2</bold>) were unveiled as NDM-1 inhibitors,
with reported IC<sub>50</sub> = 202 &#956;M and 21.8 &#956;M, and <italic toggle="yes">K<sub>i</sub>
</italic> = 39 and 1.3 &#956;M, respectively.<named-content content-type="bibref-group">
<xref rid="ref32" ref-type="bibr"/>&#8722;<xref rid="ref33" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref34" ref-type="bibr"/>
</named-content> A cocrystal structure of <bold>1</bold> in complex with NDM-1 was
solved (PDB: <ext-link xlink:href="4EXS" ext-link-type="PDB">4EXS</ext-link>), thus allowing us to determine the binding mode and key interaction
within the enzyme active site. More recent evidence also demonstrated
that other thiol-based approved drugs, namely, thiorphan (<bold>3</bold>), dimercaprol (<bold>4</bold>), and tiopronin (<bold>5</bold>),
behave as micromolar MBL inhibitors in their racemic forms, with cocrystallization
in NDM-1 confirming a binding mode superimposable to that displayed
by captopril; however, none of these compounds display broad-spectrum
inhibitory profile and relevant synergistic activity when assessed
in combination with &#946;-lactam antibiotics.<named-content content-type="bibref-group">
<xref rid="ref35" ref-type="bibr"/>&#8722;<xref rid="ref36" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref37" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Structures of <sc>l</sc>- and <sc>d</sc>-captopril (compounds <bold>1</bold> and <bold>2</bold>, respectively) and representative thiol-based
MBL inhibitors (<bold>3&#8211;5</bold>).</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c00750_0001.jpg"/></fig><p>The broad-spectrum potential of captopril on other MBLs belonging
to B1 class was proved by further crystal structures, including VIM-2
(PDB: <ext-link xlink:href="4C1D" ext-link-type="PDB">4C1D</ext-link>)
and IMP-1 (PDB: <ext-link xlink:href="4C1F" ext-link-type="PDB">4C1F</ext-link>), although residues interacting with the carboxylic group differ
based on the respective MBL and the absolute configuration of the
inhibitors carboxylic group.<xref rid="ref37" ref-type="bibr"/>
</p><p>Although
a large number of thiol-based compounds have been disclosed
lately, showing moderate to good <italic toggle="yes">in vitro</italic> inhibitory
activity, most of them lacked broad-spectrum activity or were assessed
only on a minor number of MBL isoforms. Furthermore, promising inhibitors
failed or were not evaluated against clinically relevant isolates.</p><p>The aim of this study was the exploration of captopril-inspired,
thiol-based MBL inhibitors. In particular, we employed a multicomponent
reaction protocol in order to rapidly provide, in a one-pot fashion,
indoline-based compounds rationally designed to reproduce the captopril
binding mode in the MBL active site, while also increasing the hydrophobic
interaction pattern. To get further insights into compounds&#8217;
interaction, we also explored different stereochemical outcomes at
the 2-position of the indoline core (compounds <bold>6a</bold>&#8211;<bold>f</bold>, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).
We also obtained a small subset of compounds with a merged inhibitor
design, i.e., with a thiorphan fragment embedded in our newly conceived
indoline-based structural framework (compounds <bold>7a</bold>&#8211;<bold>d</bold>, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Structures and Inhibitory Activities
of Captopril-Inspired Derivatives <bold>6a</bold>&#8211;<bold>f</bold>, <bold>7a</bold>&#8211;<bold>d</bold> and Thioester Derivatives <bold>14b,c</bold> against MBLs</title></caption><graphic id="fx1" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00750_0013.jpg"/><graphic id="fx2" position="float" orientation="portrait" xlink:href="jm5c00750_0014.jpg"/><graphic id="fx3" position="float" orientation="portrait" xlink:href="jm5c00750_0015.jpg"/><table-wrap-foot><fn id="t1fn1"><label>a</label><p>-, Not determined.</p></fn></table-wrap-foot></table-wrap><p>Furthermore, the overall efficiency and sustainability of our conceived
chemical procedure were further increased by the implementation of
a telescoped continuous flow protocol for the synthesis of the compounds&#8217;
main core. Finally, in order to validate our approach and the potential
usefulness of these novel structural motifs, the inhibitory activity
of these original compounds on relevant MBLs (NDM-1, VIM-1, VIM-2,
IMP-1, and IMP-7) was investigated by biochemical methods, while their
binding mode was rationalized through docking studies. Their synergistic
activity with carbapenems was also assessed on MBL-producing clinical
isolates.</p></sec><sec id="sec2"><label>2</label><title>Results and Discussion</title><sec id="sec2.1"><label>2.1</label><title>Rational
Design</title><p>As mentioned in the
previous paragraph, the general objective of our work was represented
by the rational design and synthesis of derivatives inspired by the
drug captopril as potential broad-spectrum inhibitors of MBL. Captopril
demonstrated activity in the micromolar range toward various MBL isoforms.
Our work focused on the synthesis of heterocyclic derivatives in order
to (i) obtain compounds with an improved inhibitory activity profile
against MBLs compared to captopril, while maintaining a broad-spectrum
profile; (ii) morph captopril structure such as to minimize the presence
of functional groups related to its original pharmacological activity
(inhibition of ACE-1, angiotensin-converting enzyme) and interaction
with similar human targets; (iii) implement diversity-oriented synthetic
protocols giving easy access to future extensive SAR exploration;
(iv) employ sustainable and advantageous continuous flow chemical
methodologies.</p><p>The rational design of the molecules first focused
on the NDM-1 enzyme, since the activity of both isomers of captopril
is well described on this peculiar MBL. The designed molecules, besides
maintaining the thiol portion essential for the interaction with the
zinc cations in the enzyme active site, were also designed to maximize
interactions in the active site pocket, with particular reference
to hydrogen bonds and hydrophobic interactions.</p><p>The general
scheme of the rational design of the new NDM-1 inhibitors
and general structures 1 and 2 is shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>(A) Hydrolysis of a &#946;-lactam antibiotic
by MBLs and general
scheme for rational design of novel MBL inhibitors; (B) subseries
1 (compounds <bold>6a</bold>&#8211;<bold>f</bold>) and subseries
2 (compounds <bold>7a</bold>&#8211;<bold>d</bold>) reported in the
present work.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c00750_0002.jpg"/></fig><p>In compounds belonging to subseries
1, we incorporated the captopril
structure within an indoline framework. According to our prediction,
the indoline system, through the fusion of an aromatic system to the
pyrrolidine ring of captopril, could allow our inhibitors to establish
additional &#960;&#8211;&#960; or hydrophobic interactions within
the active site of the enzyme including well-conserved residues in
various MBL subtypes, such as Trp87. The second structural modification,
aiming at increasing hydrophobic contacts within the active site,
was performed on the 3-position of the indoline ring on which the
effectiveness of either a spirocyclohexyl junction and the insertion
of a 3,3-dimethyl or 3,3-diethyl groups were interrogated. Finally,
the &#945;-carboxylic functionality of the captopril proline substructure
was replaced by a carboxamide moiety, keeping the hydrogen bonding
potential within MBL active, while limiting the potential issue associated
with many captopril carboxylic derivatives, which although to a lesser
extent, can behave as inhibitors of the ACE-1 enzyme (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>, compounds <bold>6a</bold>&#8211;<bold>f</bold>).</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthesis of Compounds <bold>6a</bold>&#8211;<bold>f</bold>
<xref rid="s1fn1" ref-type="fn"/>
</title></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c00750_0009.jpg"/><p>
<fn id="s1fn1"><label>a</label><p>Reagents and conditions: (a)
AcOH, 80 &#176;C, 2 h; (b) CH<sub>2</sub>Cl<sub>2</sub>, sealed tube,
50 &#176;C, 12 h; (c) TFA, DCM, 25 &#176;C, 12 h; (d) THF, NaOH, 25
&#176;C, 2 h.</p></fn>
</p></fig><p>We subsequently designed and
synthesized another small subseries
of compounds, obtained from a merging approach. Accordingly, we decided
to verify if the introduction of a structural portion belonging to
thiorphan (<bold>3</bold>) could be functional to obtaining new NDM-1
inhibitors. In particular, the 2-carboxamide functionality was replaced
with the glycyl amide moiety of thiorphan (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and <xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>, compounds <bold>7a</bold>&#8211;<bold>d</bold>).</p><fig position="float" id="sch2" fig-type="scheme" orientation="portrait"><label>2</label><caption><title>Synthesis of Compounds <bold>7a</bold>&#8211;<bold>d</bold>
<xref rid="s2fn1" ref-type="fn"/>
</title></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c00750_0010.jpg"/><p>
<fn id="s2fn1"><label>a</label><p>Reagents and conditions: (a)
DCM, sealed tube, 50 &#176;C, 12 h, (b) THF, NaOH, 25 &#176;C, 2 h.</p></fn>
</p></fig></sec><sec id="sec2.2"><label>2.2</label><title>Synthesis of Novel Indoline-Based
MBL Inhibitors</title><p>The synthesis of final compounds <bold>6a</bold>&#8211;<bold>d</bold> is reported in <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>. The 3,3-disubstituted indolenines <bold>10a</bold>&#8211;<bold>c</bold> were obtained by an interrupted
Fischer indolization reaction
between the appropriate disubstituted &#945;,&#945;&#8242;-carbaldehydes <bold>9a</bold>&#8211;<bold>c</bold> and phenylhydrazine hydrochloride <bold>8</bold> in the presence of acetic acid with the dual role of solvent
and acidic catalyst.<xref rid="ref38" ref-type="bibr"/> Indolenines <bold>10a</bold>&#8211;<bold>c</bold> were then subjected to a multicomponent
Joulli&#233;&#8211;Ugi reaction in the presence of trityl isocyanide <bold>11</bold>, prepared as previously reported, and of (<italic toggle="yes">S</italic>)-3-(acetylthio)-2-methylpropanoic acid <bold>12</bold> (a fragment
present in the side chain of captopril), using dichloromethane as
solvent under pressure at 50 &#176;C. The reactions were stirred for
12 h at 50 &#176;C.<xref rid="ref39" ref-type="bibr"/> The multicomponent
step provided compounds <bold>13a</bold>&#8211;<bold>c</bold> in
the form of diasteroisomeric mixtures in approximately 1:1 <italic toggle="yes">dr</italic> (as determined by HPLC and NMR analysis). Trityl group
deprotection carried out on the isolated diastereoisomers (separated
by reverse phase HPLC) in the presence of trifluoroacetic acid in
dichloromethane at room temperature provided the corresponding primary
amides <bold>14a</bold>&#8211;<bold>c</bold>.<xref rid="ref40" ref-type="bibr"/> The absolute stereochemistry of compound <bold>14b</bold> was verified by means of CD spectroscopy; the high similarity of
the theoretical CD spectra of (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)- and (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold>, as obtained by DFT and TDDFT calculations, with the corresponding
experimental spectra in methanol allows us to assign the absolute
configuration to the chiral center on the indoline moiety without
ambiguity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Tables S1&#8211;S5</ext-link>). Final thioester
hydrolysis with 2 N sodium hydroxide in tetrahydrofuran led to the
final free thiols <bold>6a</bold>&#8211;<bold>f</bold>.<xref rid="ref41" ref-type="bibr"/> It is worthy of note to clarify that thioester
hydrolysis required a careful fine-tuning, in order to avoid epimerization
issue. In particular, when performed over 12 h at room temperature,
the reaction led to a relevant epimerization at position 2 of the
indoline core. Satisfyingly, when reaction time was shortened to 2
h, the hydrolysis was complete and the stereochemical integrity was
fully retained (&lt;2% epimerization by NMR analysis).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Stereochemical characterization
of compound <bold>14b</bold>. CD
(&#916;&#949;) and UV (&#949;) spectra are shown in molar units;
TDDFT-calculated theoretical spectra are here shown with a 0.2 eV
blue shift for a clearer visual comparison. (A) Experimental (solid
red) and theoretical (dashed orange) spectra of (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold>. (B) Experimental (solid
blue) and theoretical (dashed cyan) spectra of (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold>.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c00750_0003.jpg"/></fig><p>The synthesis of final compounds <bold>7a</bold>&#8211;<bold>d</bold> is reported in <xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>. The formation of the indolenines was performed as described in
the previous paragraph. The following Joulli&#233;&#8211;Ugi multicomponent
step was performed in the presence of commercially available ethyl
isocyanoacetate (<bold>15</bold>) and acid <bold>12</bold>. The mixtures
of diastereomers <bold>16a,b</bold> were then separated using reverse
phase HPLC and the generation of the final compounds <bold>7a</bold>&#8211;<bold>d</bold> was carried out on the single diastereoisomers
in a single step, by alkaline hydrolysis of the ethyl ester and thioester
functionalities in high yields and no detectable epimerization events.</p><p>In order to develop reproducible, efficient, and potentially more
sustainable reaction conditions for the synthesis of our compounds,
we have developed a flow-through procedure for the synthesis of the
representative derivative <bold>13c</bold>.</p><p>The Joulli&#233;&#8211;Ugi
multicomponent reaction was carried
out in continuous flow, replacing dichloromethane with ethanol, a
green solvent (<xref rid="sch3" ref-type="fig">Scheme <xref rid="sch3" ref-type="fig"/>
</xref>). Accordingly, an equimolar solution of spiroindolenine <bold>10c</bold>, acid <bold>12</bold>, and trityl isocyanide <bold>11</bold> was
prepared in ethanol (1 mL total volume) and injected into the sample
loop. In our previous study, we optimized a multicomponent flow reaction
by delivering isocyanide and carboxylic acid through separate streams
to prevent premature side reactions and enhance the efficiency and
selectivity. The solution was injected into the flow system, and pumping
took place at a flow of 0.2 mL/min, at a temperature of 50 &#176;C
and a pressure of 7 bar, in a 15 mL tubular reactor. The total residence
time to obtain the key intermediate <bold>13c</bold> was 75 min, with
respect to the 720 min (12 h) required in batch mode.</p><fig position="float" id="sch3" fig-type="scheme" orientation="portrait"><label>3</label><caption><title>Continuous
Flow Setup for the Synthesis of Intermediate <bold>13c</bold>
</title></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c00750_0011.jpg"/></fig><p>Furthermore, having already developed a procedure
in telescoped
mode combining interrupted Fischer reaction with subsequent Joulli&#233;&#8211;Ugi
multicomponent reaction on the resulting indolenines,<xref rid="ref39" ref-type="bibr"/> we applied the method for obtaining key intermediates <bold>13a</bold>&#8211;<bold>c</bold> and <bold>16a</bold>&#8211;<bold>b</bold> (<xref rid="sch4" ref-type="fig">Scheme <xref rid="sch4" ref-type="fig"/>
</xref>), achieving comparable yields over two steps with respect to the
batch synthesis (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>), but avoiding, in this case, the isolation of the metastable spiroindolenine
intermediates and saving 95% of batch time. The developed sustainable
methodology will allow easy exploration of structure&#8211;activity
relationships and further structural diversification in a sustainable
fashion.</p><fig position="float" id="sch4" fig-type="scheme" orientation="portrait"><label>4</label><caption><title>Telescoped Approach for the Synthesis of Key Intermediates
(A) <bold>13a</bold>&#8211;<bold>c</bold> and (B) <bold>16a</bold>&#8211;<bold>b</bold>
</title></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c00750_0012.jpg"/></fig></sec><sec id="sec2.3"><label>2.3</label><title>Biological Studies and Structure&#8211;Activity
Relationship Analysis</title><p>The inhibitory activity of the compounds
was first evaluated against a panel of clinically relevant MBLs, including,
besides NDM-1, other subclass B1MBLs (VIM-1, VIM-2, IMP-1, and IMP-7)
to better assess their inhibition spectrum (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). IC<sub>50</sub> values were determined
in a kinetic fluorescence-based <italic toggle="yes">in vitro</italic> assay as
described previously.<xref rid="ref42" ref-type="bibr"/> All compounds were
preincubated with the recombinant protein for 30 min before addition
of the fluorogenic substrate fluorocillin.<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>,<xref rid="ref43" ref-type="bibr"/>
</named-content> The inhibitory activity was also determined (expressed as the percentage
of inhibition in the presence of 50 &#956;M compound) using a spectrophotometric
assay in which the hydrolysis of imipenem (the reporter substrate)
was monitored (see <xref rid="sec4" ref-type="sec">Section <xref rid="sec4" ref-type="sec"/>
</xref> for details).</p><p>Several considerations could be drawn
from these results: (a) compounds <bold>14b,c</bold>, showing a protected
thiol group in form of its thioester derivative, were rather expectedly
not or very poorly active; (b) compounds <bold>7a</bold>&#8211;<bold>d</bold>, where the primary carboxamide functionality in position
2 was replaced with the glycyl amide present in thiorphan (<bold>3</bold>), are overall less active (up to 10-fold loss of inhibitory activity)
than their corresponding 2-carboxamide analogues; (c) compounds with
a free thiol group and an unsubstituted 2-carboxamide provided the
best inhibitors, some of them showed a better activity than the reference
compound D-captopril (<bold>2</bold>). Interestingly, the orientation
of the indoline carboxamide and the nature of the hydrophobic 3-substituent
(dimethyl, diethyl, or cyclohexyl) do not seem to have a major impact
on the activity, suggesting that there is no specific interaction
with the enzyme. Notably, compounds <bold>6b</bold>&#8211;<bold>f</bold> are the most potent and interesting compounds showing a remarkably
broad spectrum of inhibition. In particular, a significant inhibition
of IMP-type enzymes, considered rather structurally divergent (in
terms of active site features and, more specifically, the nature of
the residues present in the L3 loop at positions 61, 64, 67, and 87)
from NDM- and VIM-type enzymes, was observed (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Supporting Figure S1</ext-link>). Considering these primary results,
the most promising compounds (<bold>6c</bold>&#8211;<bold>f</bold>) were selected for further investigation, and the <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values were measured for NMD-1, VIM-2,
and IMP-1 (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>).
Compound <bold>6b</bold> was not further carried on since it displayed
a lower chemical stability with respect to other compounds in the
series.</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Inhibition Constants (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub>) of Selected Compounds with Clinically
Relevant Subclass B1MBLs</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" char="&#xB1;" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (&#956;M)<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">inhibitor</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">NDM-1</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">VIM-2</th><th align="center" colspan="1" rowspan="1">IMP-1</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>6c</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">4.5&#160;&#177;&#160;0.7</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.16&#160;&#177;&#160;0.01</td><td align="left" colspan="1" rowspan="1">4.9&#160;&#177;&#160;0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6d</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.6&#160;&#177;&#160;0.1</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.08&#160;&#177;&#160;0.01<xref rid="t2fn1" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">n.d.<xref rid="t2fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6e</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.0&#160;&#177;&#160;0.1</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.10&#160;&#177;&#160;0.01</td><td align="left" colspan="1" rowspan="1">3.8&#160;&#177;&#160;0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6f</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">2.1&#160;&#177;&#160;0.2</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.16&#160;&#177;&#160;0.01<xref rid="t2fn1" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">n.d.</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Measured as <italic toggle="yes">K</italic>
<sub>d</sub> (see text for details).</p></fn><fn id="t2fn2"><label>b</label><p>n.d., not determined.</p></fn></table-wrap-foot></table-wrap><p>Interestingly,
up to 30-fold lower <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values were measured with VIM-2, despite the fact
that these compounds were initially designed to target NDM-1. Compounds <bold>6c</bold> and <bold>6e</bold> were confirmed to inhibit the three
divergent enzyme subtypes tested, confirming the rather broad spectrum
of activity of these compounds. In kinetic assays, the compounds appear
to rapidly inhibit both NDM-1 and IMP-1 (equilibrium was established
within the time of mixing), but a different behavior was observed
with VIM-2. Indeed, using a direct competition assay, a time-dependent
enzyme inhibition was observed with compounds <bold>6d</bold> and <bold>6f</bold>, allowing us to measure a pseudo-first-order rate of inactivation
(<italic toggle="yes">k</italic>
<sub>inact</sub>). The analysis of the inhibitor
concentration dependence of the <italic toggle="yes">k</italic>
<sub>inact</sub> allowed us to determine the rate constants characterizing the inhibitor-VIM-2
interaction (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>).</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>3</label><caption><title>Kinetic Parameters of VIM-2 Inhibition
by the Selected Compounds</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">k</italic>
<sub>+2</sub>/<italic toggle="yes">K</italic> (M<sup>&#8211;1</sup>&#183;s<sup>&#8211;1</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">K</italic> (&#956;M)</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">k</italic>
<sub>&#8211;2</sub> (s<sup>&#8211;1</sup>)</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>d</sub> (&#956;M)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>6d</bold>
</td><td align="left" colspan="1" rowspan="1">1.2&#160;&#215;&#160;10<sup>4</sup>
</td><td align="char" char="." colspan="1" rowspan="1">&gt;30</td><td align="left" colspan="1" rowspan="1">5.0&#160;&#215;&#160;10<sup>&#8211;3</sup>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.08&#160;&#177;&#160;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6f</bold>
</td><td align="left" colspan="1" rowspan="1">1.5&#160;&#215;&#160;10<sup>4</sup>
</td><td align="char" char="." colspan="1" rowspan="1">&gt;20</td><td align="left" colspan="1" rowspan="1">2.6&#160;&#215;&#160;10<sup>&#8211;3</sup>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.16&#160;&#177;&#160;0.01</td></tr></tbody></table></table-wrap><p>Such a behavior could
be interpreted either with the production
of the apoenzyme form after dissociation of the ternary complex (enzyme-zinc-inhibitor)
or with slow and geometrically constrained rearrangements of some
active site residues, leading to the formation of a more stable enzyme&#8211;inhibitor
complex. The association rate (<italic toggle="yes">k</italic>
<sub>+2</sub>/<italic toggle="yes">K</italic>) was similar for these compounds (&#8776;10<sup>4</sup> M<sup>&#8211;1</sup> s<sup>&#8211;1</sup>), while the <italic toggle="yes">k</italic>
<sub>&#8211;2</sub> values were low, indicating the formation
of a rather stable complex, although its formation is relatively slow. <italic toggle="yes">K</italic>
<sub>d</sub> values can be measured at steady state and
support the slow formation of an otherwise stable and potently inhibited
or inactivated form of the enzyme.</p><p>Furthermore, and to assess
one of the primary aims of this study,
i.e., redirecting the activity of captopril analogues from ACE-1 to
MBLs, the inhibitory activity of compounds <bold>6c</bold>&#8211;<bold>e</bold>, among the most potent MBL inhibitor, was also assessed
on ACE-1. Strikingly, these compounds, including analogues of both <sc>l</sc>- and <sc>d</sc>-captopril, did not show any inhibitory activity
on ACE-1, even when tested at high concentration (&lt;5% inh. at 50
&#956;M), while several captopril preparations (pure isomers and
racemic mixture) yielded the expected inhibitory activity (<xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref>). Despite captopril
being a rather good inhibitor of several MBLs (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), obtaining derivatives showing similar
or better potency on MBLs without cross-inhibition of ACE-1 represents
a significant achievement.</p><table-wrap position="float" id="tbl4" orientation="portrait"><label>4</label><caption><title>Inhibition of ACE-1
by Selected Compounds
and Captopril<xref rid="t4fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">inhibition of ACE-1 activity (%)</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="1">
<sc>d</sc>-captopril</td><td align="center" colspan="1" rowspan="1">8.9&#160;&#177;&#160;0.1</td></tr><tr><td align="center" colspan="1" rowspan="1">
<sc>l</sc>-captopril</td><td align="center" colspan="1" rowspan="1">&gt;99.5</td></tr><tr><td align="center" colspan="1" rowspan="1">captopril<xref rid="t4fn2" ref-type="table-fn"/>
</td><td align="center" colspan="1" rowspan="1">98&#160;&#177;&#160;1</td></tr><tr><td align="center" colspan="1" rowspan="1">
<bold>6c</bold>
</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="center" colspan="1" rowspan="1">
<bold>6d</bold>
</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="center" colspan="1" rowspan="1">
<bold>6e</bold>
</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr></tbody></table><table-wrap-foot><fn id="t4fn1"><label>a</label><p>Assays were performed in the presence
of 50 &#956;M inhibitor in the reaction mixture (see the <xref rid="sec4" ref-type="sec">Experimental Section</xref> for details).</p></fn><fn id="t4fn2"><label>b</label><p>Commercially available captopril,
racemic mixture (Cayman Chemical cat. no. 15313).</p></fn></table-wrap-foot></table-wrap><p>Encouraged by these positive results,
the potential synergistic activity
of these compounds was tested in combination with imipenem on a panel
of clinical isolates producing several different MBL enzymes (<xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>). Unfortunately,
the potentiation of imipenem in the presence of most of the compounds
was limited (no or unsignificant 2-fold decrease of the MIC value),
indicating that, despite a good inhibitory activity of some of the
tested compounds in enzyme assays (e.g., <bold>6e</bold>, <bold>6f</bold>), such molecules are apparently unable to reach periplasmic concentrations
compatible with the inhibition of the MBL in the bacterial cell. Such
results are not uncommon and likely rely on the lack of suitable properties
of the molecules to readily diffuse through the bacterial outer membrane,
whose presence still represents one of the major issues in the optimization
of compounds targeting Gram-negative bacteria. However, compound <bold>6d</bold> showed a more significant 8-fold reduction of the imipenem
MIC, although on a limited number of strains, including a VIM-1-producing <italic toggle="yes">K. pneumoniae</italic> isolate and an IMP-1-producing <italic toggle="yes">P. aeruginosa</italic> isolate.</p><table-wrap position="float" id="tbl5" orientation="portrait"><label>5</label><caption><title>Synergistic
Activity of MBLi Compounds
(Tested at a Final Concentration of 32 &#956;g/mL, Unless Otherwise
Specified) with Imipenem on MBL-Producing Clinical Isolates</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="10" align="center" char="." rowspan="1">imipenem
MIC (&#956;g/mL)<xref rid="t5fn1" ref-type="table-fn"/>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">E. coli</italic> SI-M001 (<italic toggle="yes">bla</italic>
<sub>NDM&#8209;1</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">E. coli</italic> SI-G001 (<italic toggle="yes">bla</italic>
<sub>NDM&#8209;4</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">E. coli</italic> SI&#8211;N003 (<italic toggle="yes">bla</italic>
<sub>NDM&#8209;7</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">K. pneumoniae</italic> T2301 (<italic toggle="yes">bla</italic>
<sub>NDM&#8209;1</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">K. pneumoniae</italic> 7023 (<italic toggle="yes">bla</italic>
<sub>VIM&#8209;1</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">K. pneumoniae</italic> T2216 (<italic toggle="yes">bla</italic>
<sub>VIM&#8209;1</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">S. marcescens</italic> SI-1591 (<italic toggle="yes">bla</italic>
<sub>VIM&#8209;2</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">K. pneumoniae</italic> VA<italic toggle="yes">-</italic>416/02 (<italic toggle="yes">bla</italic>
<sub>VIM&#8209;4</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">A. baumannii</italic> AC-54/97 (<italic toggle="yes">bla</italic>
<sub>IMP&#8209;2</sub>
<sup>+</sup>)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">P. aeruginosa</italic> T2325 (<italic toggle="yes">bla</italic>
<sub>IMP&#8209;1</sub>
<sup>+</sup>)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">None</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">64</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6b</bold>
</td><td align="char" char="." colspan="1" rowspan="1">-<xref rid="t5fn2" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">16<xref rid="t5fn3" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">4<xref rid="t5fn3" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">64<xref rid="t5fn3" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6c</bold>
</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6d</bold>
</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">16<xref rid="t5fn3" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">2<xref rid="t5fn3" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">16<xref rid="t5fn3" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6e</bold>
</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>6f</bold>
</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7a</bold>
</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7b</bold>
</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">8<xref rid="t5fn3" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">4<xref rid="t5fn3" ref-type="table-fn"/>
</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">32<xref rid="t5fn3" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7c</bold>
</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7d</bold>
</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">(<italic toggle="yes">S,R</italic>&#8242;)-<bold>14b</bold>
</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">(<italic toggle="yes">S,S</italic>&#8242;)-<bold>14c</bold>
</td><td align="char" char="." colspan="1" rowspan="1">16</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">32</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">64</td><td align="char" char="." colspan="1" rowspan="1">-</td><td align="char" char="." colspan="1" rowspan="1">8</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">128</td><td align="char" char="." colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="t5fn1"><label>a</label><p>Reported MIC values
are the median
from three independent experiments.</p></fn><fn id="t5fn2"><label>b</label><p>-, Not determined.</p></fn><fn id="t5fn3"><label>c</label><p>Compound tested at a final concentration
of 128 &#956;g/mL.</p></fn></table-wrap-foot></table-wrap><p>We further
investigated the effects of the most promising compound <bold>6d</bold> to restore the antibacterial effect of imipenem in a growth
inhibition assay (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>).</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Growth inhibition assay. Growth curves of (A) NDM-1 expressing <italic toggle="yes">K. pneumoniae</italic> (T2301), (B) IMP-1 expressing <italic toggle="yes">P. aeruginosa</italic> (T2325), and (C) VIM-1 expressing <italic toggle="yes">K. pneumoniae</italic> (T2216) in the absence and presence
of imipenem at 0.5 &#215; MIC &#177; <bold>6d</bold> at 128 &#956;g/mL.
Purple = growth control; red = <bold>6d</bold>; blue = imipenem; green
= imipenem plus <bold>6d</bold>.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="jm5c00750_0004.jpg"/></fig><p>As shown in the growth curves in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>, the presence of imipenem at 0.5 &#215;
MIC significantly delayed the growth of MBL-producing strains, although
little difference could be observed after 24 h of incubation in the
presence of either imipenem alone or of the combination. Interestingly,
when MBL inhibitor <bold>6d</bold> was tested at 128 &#956;g/mL in
the presence of 0.5 &#215; MIC of imipenem, the inhibitory potential
of imipenem was further prolonged for several hours. MBL inhibitor <bold>6d</bold> alone did not exhibit any intrinsic antibacterial activity
up to 128 &#956;g/mL. These data highlight the promising potential
of <bold>6d</bold> and prompt a further optimization campaign in order
to improve the cell-penetrating profile and this new class of broad-spectrum
MBL inhibitors.</p><p>From this focused set of compounds, it is possible
to infer a series
of significant hints for further design and optimization: (i) most
of the developed compounds showed an improved inhibition profile on
NDM-1, with respect to the progenitors <sc>l</sc>- and <sc>d</sc>-captopril;
(ii) as expected, compounds bearing the capping acetyl moiety on the
thiol group were completely inactive against NDM-1, thus confirming
the importance of the free thiol group for the interaction with the
zinc ions in the catalytic site; (iii) in line with the trend observed
for <sc>l</sc>- and <sc>d</sc>-captopril isomers, stereochemistry
at the 2-position of the indoline system seems to be only moderately
relevant in the first subseries of compounds (<bold>6a</bold>&#8211;<bold>f</bold>) and slightly more influential in the second subseries (<bold>7a</bold>&#8211;<bold>d</bold>), with the <italic toggle="yes">R</italic> configuration
guaranteeing in both cases better performances in terms of inhibitory
activity; (iv) compound <bold>6d</bold> demonstrated negligible activity
on ACE, thus validating our design while averting off-target liability
for this newly conceived class of compounds.</p><p>In order to elucidate
and unveil the interactions of the compounds
at the molecular level, the possible binding mode of selected inhibitors <bold>6d</bold>, <bold>6c</bold>, and <bold>6e</bold> against the catalytic
site of NDM-1, VIM-1, VIM-2, IMP-1, and IMP-7 isoforms was elucidated
by molecular docking and dynamics (MD) simulations, with the aim to
rationalize the inhibitory activity results while obtaining key hints
for further design activity.</p><p>Before docking, the evaluation
of the entropic and enthalpic contributions
of crystallographic water molecules within the catalytic site was
carried out by SZMAP software.<xref rid="ref23" ref-type="bibr"/> Water
molecules estimated to provide a positive contribution to ligand binding
were retained in the receptor&#8217;s structure during docking. Molecular
docking was carried out with the GOLD program (The Cambridge Crystallographic
Data Centre),<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>,<xref rid="ref24" ref-type="bibr"/>
</named-content> whose accuracy was preliminarily
verified by redocking the cocrystallized inhibitor into the X-ray
structures of MBL isoforms investigated in this work (RMSD of docking
vs crystallographic pose &lt;1.00 &#197;, data not shown).</p><p>We
first took into consideration the captopril binding to NDM-1;
in particular, we considered the two solved X-ray complexes of NDM-1
protein with <sc>l</sc>-captopril (PDB code: <ext-link xlink:href="4EXS" ext-link-type="PDB">4EXS</ext-link>, <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>A)<xref rid="ref33" ref-type="bibr"/> and <sc>d</sc>-captopril (PDB code: <ext-link xlink:href="5ZJ2" ext-link-type="PDB">5ZJ2</ext-link>, <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>B),<xref rid="ref34" ref-type="bibr"/> from where it can
be noticed that the L3 of NDM-1 assumes two different conformations
in the presence of these two inhibitors (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>C). In addition, a different orientation
of the proline ring can be observed in the X-ray cocrystal structure
of <sc>d</sc>-captopril, which allows further hydrophobic interactions
with Met67 and especially Phe70 residues in the L3, thus supporting
the closed conformation of the loop. The different orientation of
the carboxylate group also allows <sc>d</sc>-Captopril to establish
a water-bridged H-bond interaction with Lys211 (Lys224 in the standard
numbering scheme) in loop L10 and another H-bond with the conserved
Asn220 (Asn233 in the standard numbering scheme) that is known to
play an important role in substrate positioning and &#946;-lactam
hydrolysis in NDM-1 and other subclass B1MBLs. These two interactions
increase the binding of <sc>d</sc>-Captopril with the active site
of NDM-1 and contribute to its higher potency compared to that of <sc>l</sc>-Captopril. Similar findings were observed by monitoring the
interaction of <sc>d</sc>- and <sc>l</sc>-Captopril to VIM-2 in available
X-ray crystallography structures (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Supporting Figure S2</ext-link>), with the only difference relating to the direct interaction
between the carboxylate moiety of <sc>d</sc>-Captopril to Arg205 in
VIM-2 compared to the water-bridged interaction to Lys211 of NDM-1
such as described above.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>X-ray crystallography structure of NDM-1 in
complex with <sc>l</sc>- and <sc>d</sc>-captopril. (A) X-ray crystallography
complex of
NDM-1 (pink, &#8220;open&#8221; conformation, PDB-ID: <ext-link xlink:href="4EXS" ext-link-type="PDB">4EXS</ext-link>) with <sc>l</sc>-captopril (green sticks); (B) X-ray crystallography complex of NDM-1
(light blue, &#8220;closed&#8221; conformation, PDB-ID: <ext-link xlink:href="5ZJ2" ext-link-type="PDB">5ZJ2</ext-link>) with <sc>d</sc>-captopril (yellow sticks); (C) superposition of NDM-1 structures
in complex with <sc>l</sc>-captopril (pink) and <sc>d</sc>-captopril
(light blue). Polar interactions are highlighted by black dashed lines.
Residues involved in zinc coordination and in binding <sc>l</sc>-
and <sc>d</sc>-captopril are shown as sticks and are labeled.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="jm5c00750_0005.jpg"/></fig><p>Compounds investigated in this work were first
docked against the
&#8220;open&#8221; conformation of NDM-1 (PDB code: <ext-link xlink:href="4EXS" ext-link-type="PDB">4EXS</ext-link>, data not shown),<xref rid="ref33" ref-type="bibr"/> failing to explain the different inhibitory
activities observed <italic toggle="yes">in vitro</italic> in the enzymatic assays.
In contrast, performing the docking on the &#8220;closed&#8221;
conformation of NDM-1 in complex with <sc>d</sc>-captopril (PDB code: <ext-link xlink:href="5ZJ2" ext-link-type="PDB">5ZJ2</ext-link>)<xref rid="ref34" ref-type="bibr"/> provided a suitable correlation between predicted binding
modes and experimental results, also supporting that compounds of
both the two subseries presenting the <italic toggle="yes">R</italic> configuration
at the 2-position of the indoline ring system have a more favorable
binding mode and docking score compared to their <italic toggle="yes">S</italic> counterparts. Computational results obtained with the most representative
compounds of the series, based on chemical structure and biological
activity, are illustrated below.</p><p>Based on the IC<sub>50</sub> values of <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>, <bold>6d</bold> was initially docked to
the active site of NDM-1, VIM-1, and IMP-7. Docking results (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>) clearly indicate
that the sulfhydryl moiety of <bold>6d</bold> coordinates the two
catalytic Zn&#173;(II) ions by positioning them in the middle of them in
all tested isoforms. In NDM-1, <bold>6d</bold> establishes direct
H-bond interactions with Asn220 and Lys211 from the loop L10, while
an additional interaction to Lys211 is bridged by a water molecule
(involving the amide nitrogen of <bold>6d</bold>). The indole ring
participates in a &#960;&#8211;&#960; stacking interaction with
His250, and it is docked within a hydrophobic region composed of Met67,
Phe70, Val73, and Trp93 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A). With VIM-1, <bold>6d</bold> is H-bonded to the
conserved Asn210(233) and binds to L3 through a &#960;-&#960; stacking
interaction with Tyr67 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>B). On IMP-7, <bold>6d</bold> establishes H-bonds with Asn185,
His215, and Glu41, while it interacts with the L3 through &#960;-&#960;
stacking interaction with Trp46 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>C). For the sake of clarity, residue numbering
corresponds to the crystallographic structures used in this molecular
modeling study.</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Predicted binding mode of <bold>6d</bold> against (A)
NDM-1 (colored
beige; PDB-ID: <ext-link xlink:href="5ZJ2" ext-link-type="PDB">5ZJ2</ext-link>), (B) VIM-1 (colored Bordeaux; PDB-ID: <ext-link xlink:href="7UP2" ext-link-type="PDB">7UP2</ext-link>) and (C) IMP-7 (colored green; homology
model). <bold>6d</bold> is shown as cyan sticks, and the two zinc
atoms as a gray sphere. Polar interactions are highlighted by black
dashed lines, residues contacted by the ligand are shown as sticks,
while residues within about 5 &#197; from the ligands are shown as
lines. Water molecules are represented by small red spheres.</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="jm5c00750_0006.jpg"/></fig><p>Based on the <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> data
of <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>, <bold>6c</bold> and <bold>6e</bold> were docked to the catalytic site of NMD-1,
VIM-2, and IMP-1 MBLs. Also in this case, docking results clearly
indicate that Zn&#173;(II) coordination by the sulfhydryl moiety in the
middle of the two zinc ions is a crucial binding feature for <bold>6c</bold> and <bold>6e</bold> to anchor the catalytic site. Notably, <bold>6c</bold> and <bold>6e</bold> have a highly superimposable binding
pose to NDM-1, VIM-2, and IMP-1, which may explain their similarity
in <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values. In NDM-1, <bold>6c</bold> and <bold>6e</bold> are H-bonded to Asn220 and Lys211,
while the indole ring participates in a T-shaped &#960;-stacking
interaction with Phe70 (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>A,B). In VIM-2, both compounds establish H-bond interactions
with the Zn-binding His240, Asn210, and Arg205, while an additional
T-shaped &#960;-stacking interaction with Tyr67 from the L3 loop
is observed (<xref rid="fig7" ref-type="fig">Figures <xref rid="fig7" ref-type="fig"/>
</xref>C and <xref rid="fig6" ref-type="fig"/>D). Finally, within IMP-1, <bold>6c</bold> and <bold>6e</bold> establish an H-bond interaction with Asn185,
while the indole ring is &#960;&#8211;&#960; stacked with His215
(<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>E,F).</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Predicted binding
mode of <bold>6c</bold> and <bold>6e</bold> against
(A, B) NDM-1 (colored beige; PDB-ID: <ext-link xlink:href="5ZJ2" ext-link-type="PDB">5ZJ2</ext-link>), (C, D) VIM-2 (colored dark green; PDB-ID: <ext-link xlink:href="6JN6" ext-link-type="PDB">6JN6</ext-link>) and (E, F) IMP-1
(colored light blue, PDB-ID: <ext-link xlink:href="7YHA" ext-link-type="PDB">7YHA</ext-link>). <bold>6c</bold> is shown as green sticks, while <bold>6e</bold> is shown as magenta sticks, the two zinc atoms as a gray
sphere. Polar interactions are highlighted by black dashed lines,
residues contacted by the ligand are shown as sticks, while residues
within about 5 &#197; from the ligands are shown as lines. Water molecules
are represented by small red spheres.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="jm5c00750_0007.jpg"/></fig><p>Despite the known sequence and structural differences between MBL
isoforms investigated in this work, docking results highlight a common
interaction pattern for <bold>6c</bold>, <bold>6d</bold>, and <bold>6e</bold> within the catalytic site of the enzymes. Of note, MBL
inhibitors bind the catalytic Zn&#173;(II) ions as well as key residues
that are involved in zinc coordination and in &#946;-lactam substrate
recognition and chemical transformation, providing structural hints
that corroborate the broad-spectrum efficacy of <bold>6c</bold>&#8211;<bold>6e</bold> such as observed by experiments.</p><p>To assess the accuracy
of docking poses and to evaluate their time
persistency, MD simulations were performed on a representative system,
i.e., the complex between <bold>6d</bold> and NDM-1. Unrestrained
all-atom MD trajectories were generated for 500 ns in explicit water
solvent and further analyzed for the root mean square deviation (RMSD)
and MD frame clustering. The RMSD plot (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>) shows that the interaction between <bold>6d</bold> and
NDM-1 is stable over the simulation time.</p><p>The further visual
inspection of the most representative MD frame
(i.e., the centroid of the cluster with the highest frame population
as extracted by cluster analysis) suggests that <bold>6d</bold> stably
binds the catalytic site in a conformation that resembles the docking
pose (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). In
fact, Zn&#173;(II) coordination by the sulfhydryl moiety and H-bond interactions
with Lys211 and Asn220, as identified by docking, are conserved in
the MD pose; similarly, the crystallographic water molecule bridging <bold>6d</bold> to Lys211 is stably found also in the MD trajectory (red
sphere in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>).
Nevertheless, a slight conformational change in the catalytic site
was observed by MD, which is mostly due to a reciprocal and lipophilic-based
approach of the indole ring of <bold>6d</bold> and the hydrophobic
portion of NDM-1 within the loop L3 composed of Met67, Phe70, Val73,
and Trp93 (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>).</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Representation of the
most representative frame derived from the
cluster analysis on the MD trajectory (cluster with the highest frame
population), NDM-1 is represented by pink cartoon, while <bold>6d</bold> is shown as light-green sticks. The two zinc atoms are represented
as a gray sphere. Polar interactions are highlighted by black dashed
lines, residues contacted by the ligand are shown as sticks, while
residues within about 5 &#197; from the ligands are shown as lines.
Water molecules are represented by small red spheres (structure from
molecular dynamics).</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="jm5c00750_0008.jpg"/></fig><p>Overall, docking simulations
coupled with MD provided a detailed
picture of the interaction between small-molecule inhibitors and target
MBLs, which paves the way to the further optimization of these derivatives
as well as the design of additional chemotypes of MBL inhibitors.</p></sec></sec><sec id="sec3"><label>3</label><title>Conclusions</title><p>In summary, the present study
describes the design, synthesis,
and biological evaluation of two indoline-based subseries of MBL inhibitors
inspired by captopril drug. In order to develop an efficient, versatile,
and sustainable synthetic protocol, the generation of the compounds
employed a one-pot multicomponent reaction, implemented in both batch
and flow modes. Most of the designed compounds showed improved NDM-1
inhibitory activity with respect to the captopril parent compound.
Several indoline-based derivatives also presented broad-spectrum activity
on clinically relevant MBL subtypes. Notably, for some of the compounds,
a significant inhibition of IMP-type enzymes was observed, despite
these enzymes being considered structurally divergent (in terms of
active site features) from NDM- and VIM-type enzymes.</p><p>The inhibition
kinetics were also elucidated, and the compounds
appear to inhibit both NDM-1 and IMP-1 very quickly, but different
behavior was observed with VIM-2. Indeed, using a direct competition
assay, a time-dependent enzyme inhibition was observed with compounds <bold>6d</bold> and <bold>6f</bold>, allowing us to measure a pseudo-first-order
rate of inactivation (<italic toggle="yes">k</italic>
<sub>inact</sub>). The analysis
of the inhibitor concentration dependence of the <italic toggle="yes">k</italic>
<sub>inact</sub> allowed determination of the rate constants characterizing
the inhibitor-VIM-2 interaction.</p><p>Furthermore, the inhibitory
activity of compound <bold>6d</bold>, one of the most potent MBL inhibitors
of the series, was also assessed
on the ACE-1 enzyme, the original target of <sc>l</sc>-captopril drug.
Strikingly, this compound was completely inactive on ACE-1, thus averting
this off-target effect for the newly conceived class of compounds.</p><p>When assessed for its synergistic activity in combination with
imipenem on a panel of MBL-producing clinical isolates, compound <bold>6d</bold> showed a significant 4-fold reduction of the imipenem MIC
in a VIM-1-producing <italic toggle="yes">K. pneumoniae</italic> isolate
and in an IMP-1-producing <italic toggle="yes">P. aeruginosa</italic> isolate. On the contrary, compounds <bold>6e,f</bold>, despite a
good <italic toggle="yes">in vitro</italic> inhibitory profile, proved unable to
reduce the imipenem MIC, possibly in relation to their limited diffusion
through the outer membrane, leading to periplasmic concentrations
insufficient to inhibit the MBL in the bacterial cell, although other
mechanisms, such as active efflux, could not be ruled out.</p><p>Growth
inhibition assay in combination with imipenem demonstrated
that compound <bold>6d</bold> was able to prolong the inhibitory potential
of imipenem for several hours. Collected together, these data highlight
the promising potential of <bold>6d</bold> and prompt a further optimization
campaign in order to improve the potency and cell-penetrating profile
of this new class of broad-spectrum MBL inhibitors.</p><p>In order
to elucidate and unveil the interaction of the compounds
at the molecular level, the possible binding mode of selected inhibitors,
namely, <bold>6c</bold>, <bold>6d</bold>, and <bold>6e</bold>, against
the catalytic site of selected NDM-, VIM-, and IMP-type MBLs was elucidated
by detailed computational studies. Overall, docking simulations coupled
with molecular dynamics provided a detailed picture of the interaction
between the best-performing compounds of the series and the target
MBL variants, which will pave the way for further optimization. Future
activities aimed at improving the potency and expanding the spectrum
of inhibition for this newly conceived captopril-inspired MBL inhibitors
will include rational stepwise modification or replacement of the
original captopril side chain as well as explorations of the nature
and the length of the amide moiety of thiorphan-like series.</p></sec><sec id="sec4"><label>4</label><title>Experimental Section</title><sec id="sec4.1"><label>4.1</label><title>Chemistry</title><sec id="sec4.1.1"><label>4.1.1</label><title>General Remarks</title><p>Unless otherwise
specified, the materials were purchased from commercial suppliers
and used without further purification. TLC analysis was conducted
using aluminum foil-supported thin-layer silica gel chromatography
plates (F254 indicator). Column chromatography was performed using
230&#8211;400 mesh and 60 &#197; pore diameter silica gel. For <sup>1</sup>H NMR and <sup>13</sup>C NMR measurements, an accurately weighed
amount of analyte (about 5.0&#8211;10.0 mg) was dissolved in 600
&#956;L of dimethyl sulfoxide (DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>). The mixture was transferred into a 5 mm NMR tube, and the spectra
were acquired on a Bruker Advance 400 MHz spectrometer by using the
residual signal of the deuterated solvent as internal standard. Splitting
patterns are described as singlet (s), doublet (d), triplet (t), quartet
(q), and broad (br); the values of chemical shifts (&#948;) are given
in ppm and coupling constants (J) in Hertz (Hz). NMR data were processed
with MestreNova (ver. 8.1.1, Mestrelab Research). ESI-MS spectral
analysis was carried out on a mass spectrometer LTQ-XL. High-resolution
ESI-MS spectra were performed on a Thermo LTQ Orbitrap XL mass spectrometer.
The spectra were recorded by infusion into the ESI source using MeOH
as the solvent. HPLC was performed with a Waters Model 510 pump equipped
with a Waters Rheodyne injector and a differential refractometer,
model 401. Luna 5 &#956;m PFP (2) 100A HPLC Column 250 mm &#215;
10 mm was employed. Purity of the compounds is &gt;95%.</p></sec><sec id="sec4.1.2"><label>4.1.2</label><title>Continuous Flow Synthesis of Indolenines <bold>10a</bold>&#8211;<bold>c</bold> (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>)</title><p>Chemical transformations in flow
were realized using a self-made flow reactor: two Waters P510 HPLC
pumps were connected, each to a Rheodyne 9010 injection valve, each
equipped with a 1 mL sample loop (SL) made from PTFE tubing and an
injection port for disposable syringes. The injection valves were
further connected via a T-piece to a coiled PTFE tubing of a 15 mL
volume. The coil was immersed in a silicone oil bath for controlling
the reaction temperatures. The tubular reactor finished as a back
pressure regulator (BPR), which was either spring mechanism-based
(6.7 bar) or simply a PEEK capillary of defined length (1.7 bar).
Product containing exiting streams were collected directly in a flask.
An aliquot of the collected phase was used for analysis by GC-MS.
Reagents were prepared for loading into the sample loops according
to one of the following methods: 0.25 mmol aldehyde +0.25 mmol PhNHNH<sub>2</sub>&#183;HCl in 1 mL of EtOH, heated to 50 &#176;C for 5 min
prior to loading into the SL; SL B: (equiv.-1) HCl in 1 mL of EtOH.
3,3-Dimethyl-3<italic toggle="yes">H</italic>-indole <bold>10a</bold>, 3,3-diethyl-3<italic toggle="yes">H</italic>-indole <bold>10b</bold>, spiro&#173;[cyclohexane-1,3&#8242;-indole] <bold>10c</bold> were synthesized in according to a previously reported
procedure.<xref rid="ref38" ref-type="bibr"/>
</p></sec><sec id="sec4.1.3"><label>4.1.3</label><title>Batch
Synthesis of Key Intermediates <bold>13a</bold>&#8211;<bold>c</bold>, <bold>16a</bold>&#8211;<bold>b</bold> (General Procedure A)</title><p>Following the reported procedure
in the literature,<xref rid="ref39" ref-type="bibr"/> indolenine <bold>10a</bold>&#8211;<bold>c</bold> (3 mmol) were dissolved in DCM (0.3 M), followed
by the addition of the corresponding amino acid (1.0 equiv) and isocyanide
(1.0 equiv). The reaction mixture was stirred for 24&#8211;30 h at
50 &#176;C in a sealed tube. Then, DCM was evaporated under vacuum
to achieve the crude residue that was subjected to column chromatography
(SiO<sub>2</sub>, corresponding eluent) and to HPLC to afford a diastereomeric
mixture.</p></sec><sec id="sec4.1.4"><label>4.1.4</label><title>Flow Synthesis of Key
Intermediates <bold>13a</bold>&#8211;<bold>c</bold>, <bold>16a</bold>&#8211;<bold>b</bold> (General Procedure B)</title><p>Chemical transformations
in flow
were realized using a self-made flow reactor: Waters P510 HPLC pumps
were connected to a Rheodyne 9010 injection valve, equipped with a
1 mL sample loop made from PTFE tubing and an injection port for disposable
syringes. The injection valve was further connected to a coiled PTFE
tubing of a 15 mL volume. The coil was immersed in a silicone oil
bath for controlling reaction temperatures. The tubular reactor was
fitted to a mechanical back pressure regulator (BPR) of approximately
7 bar. Products containing exiting streams were collected directly
in a flask.</p><p>A solution of indolenines <bold>10a</bold>&#8211;<bold>c</bold> (0.25 mmol), the suitable acid (1 equiv), and the appropriate
isocyanide (1 equiv) was prepared in EtOH (1 mL total solution volume).
The flow reactor was heated to 80 &#176;C. EtOH was used as solvent
at a total flow rate of 0.2 mL/min to move the reaction mixture through
the coil reactor for a residence time of 75 min.</p></sec><sec id="sec4.1.5"><label>4.1.5</label><title>Batch Synthesis of Compounds <bold>14a</bold>&#8211;<bold>c</bold> (General Procedure C)</title><p>The multicomponent
key intermediates <bold>13a</bold>&#8211;<bold>c</bold> were dissolved
in DCM/TFA 1:1, and the reaction was stirred overnight at room temperature.
The mixture was washed with NaHCO<sub>3</sub> and extracted with DCM.
The solvent was evaporated under a vacuum, and the reaction was purified
by chromatography on silica gel.</p></sec><sec id="sec4.1.6"><label>4.1.6</label><title>Batch
Synthesis of Final Products <bold>6a</bold>&#8211;<bold>f</bold>, <bold>7a</bold>&#8211;<bold>d</bold> (General Procedure D)</title><p>The
ester intermediates were dissolved
in THF/NaOH (1:3, 0.5 mL/1.5 mL), and the reaction was stirred for
2 h at room temperature. The reaction was quenched with 2 N HCl and
extracted with ethyl acetate. Then, the solvent was evaporated under
vacuum, and the reaction was purified by chromatography on silica
gel to afford the final title products.</p></sec><sec id="sec4.1.7"><label>4.1.7</label><title>(2<italic toggle="yes">S</italic>)-3-((3,3-Dimethyl-2-(tritylcarbamoyl)&#173;indolin-1-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
(<bold>13a</bold>)</title><p>According to general procedure A, a mixture
of 3,3-dimethyl-3<italic toggle="yes">H</italic>-indole <bold>10a</bold>, (351
mg, 2.42 mmol), 3-(acetylthio)-2-methylpropanoic acid <bold>12</bold> (242 &#956;L, 2.66 mmol), and trityl isocyanide <bold>11</bold> (716 mg, 2.66 mmol) was dissolved in DCM (5 mL) in a sealed tube
at 50 &#176;C for 30 h. The crude product was purified by chromatography
on silica gel with hexane/EtOAc (85:15) to yield the multicomponent
products in the form of a diastereomeric mixture. The diastereoisomers
were subjected to reversed-phase HPLC using MeOH/H<sub>2</sub>O (85:15)
as the eluent (flow rate 3.00 mL/min). Total yield: 26% (<italic toggle="yes">dr</italic> 1:1).</p><p>
<bold>(</bold>
<italic toggle="yes">
<bold>S</bold>
</italic>,<italic toggle="yes">
<bold>S</bold>
</italic>
<bold>&#8242;)-13a</bold>: Yellowish solid; <italic toggle="yes">R</italic>
<sub>f</sub> = 0.38 (H/E 7:3). <sup>1</sup>H NMR (700 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 9.27 (s, 1H), 7.90 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.30&#8211;7.26 (m, 15H), 6.97 (m, 3H),
4.98 (s, 1H), 3.15 (dt, <italic toggle="yes">J</italic> = 13.6, 6.3 Hz, 2H), 2.89
(h, <italic toggle="yes">J</italic> = 6.8 Hz, 1H), 2.29 (s, 3H), 1.29 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 3H), 1.24 (s, 3H), 1.16 (s, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 195.8,
168.5, 144.6, 129.2, 128.8, 128.0, 127.7, 127.0, 126.7, 71.2, 44.9,
31.5, 31.1, 29.5, 29.2, 20.4, 18.2.</p><p>
<italic toggle="yes">t</italic>R HPLC:
12.57 min. [&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;311.54 (<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>36</sub>H<sub>36</sub>N<sub>2</sub>O<sub>3</sub>S<sup>+</sup>: 577.24475; found: 577.25128.</p><p>
<bold>(</bold>
<italic toggle="yes">
<bold>S</bold>
</italic>,<italic toggle="yes">
<bold>R</bold>
</italic>
<bold>&#8242;)-13a</bold>. Yellowish solid; <italic toggle="yes">R</italic>
<sub>f</sub> = 0.38 (H/E 7:3). <sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 9.18 (s, 1H), 7.94 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.28 (m, 10H), 7.22&#8211;7.15 (m, 3H), 7.14&#8211;7.06
(m, 2H), 7.05 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 6.99&#8211;6.92
(m, 2H), 4.98 (s, 1H), 3.09 (dd, <italic toggle="yes">J</italic> = 13.4, 6.2 Hz,
1H), 3.02 (dd, <italic toggle="yes">J</italic> = 13.3, 7.5 Hz, 1H), 2.81&#8211;2.75
(m, 2H), 2.39 (s, 2H), 1.27 (s, 3H), 1.24 (s, 3H), 1.00 (d, <italic toggle="yes">J</italic> = 3.9 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 195.5, 172.9, 168.70, 144.7, 142.3,
140.9, 128.8, 128.0, 127.5, 126.9, 124.1, 121.9, 116.7, 72.4, 70.4,
45.1, 38.4, 33.2, 31.9, 31.1, 29.5, 21.5, 17.7.</p><p>tR HPLC: 11.49
min. [&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;21.32
(<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>36</sub>H<sub>36</sub>N<sub>2</sub>O<sub>3</sub>S<sup>+</sup>: 577.24475; found: 577.25128.</p></sec><sec id="sec4.1.8"><label>4.1.8</label><title>(<italic toggle="yes">S</italic>)-3-((<italic toggle="yes">S</italic>)-2-Carbamoyl-3,3-(dimethylindolin-1-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
((<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14a</bold>)</title><p>According to procedure C, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>13a</bold> (90 mg, 0.15 mmol) was dissolved in DCM/TFA
1:1 (4.5 mL/4.5 mL) and the reaction was stirred overnight at room
temperature. The mixture was washed with NaHCO<sub>3</sub> and extracted
with DCM. Then, the solvent was evaporated under vacuum, and the reaction
was purified by chromatography on silica gel with hexane/EtOAc (1:1)
to yield the product as a yellowish solid. Yield: 54% (27 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.17 (H/E 1:1).</p><p>
<sup>1</sup>H NMR
(700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.08 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.78 (s, 1H), 7.38 (s, 1H), 7.19 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.16 (t, <italic toggle="yes">J</italic> = 7.7 Hz, 1H),
7.02 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 4.58 (s, 1H), 3.04 (dd, <italic toggle="yes">J</italic> = 13.2, 5.8 Hz, 1H), 2.99 (dd, <italic toggle="yes">J</italic> = 13.2,
8.6 Hz, 1H), 2.75 (dq, <italic toggle="yes">J</italic> = 12.7, 6.2 Hz, 1H), 2.33
(s, 3H), 1.32 (d, <italic toggle="yes">J</italic> = 18.2 Hz, 6H), 1.08 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 195.0, 173.0, 170.4, 141.9, 140.1,
127.2, 123.7, 121.8, 116.3, 72.6, 43.2, 38.2, 32.7, 31.9, 30.5, 22.2,
17.1.</p><p>[&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;52.64 (<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S<sup>+</sup>: 335.14; found: 335.14</p></sec><sec id="sec4.1.9"><label>4.1.9</label><title>(<italic toggle="yes">S</italic>)-1-((<italic toggle="yes">S</italic>)-3-Mercapto-2-methylpropanoyl)-3,3-dimethylindoline-2-carboxamide
(<bold>6a</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">S<italic toggle="yes">&#8242;</italic>
</italic>)-<bold>14a</bold> (20
mg, 0.06 mmol) was dissolved in THF/NaOH (1:3, 0.5 mL/1.5 mL) and
the reaction was stirred for 2 h at room temperature. The mixture
was quenched with 2 N HCl and extracted with ethyl acetate. Then,
the solvent was evaporated under vacuum and the reaction was purified
by chromatography on silica gel with hexane/EtOAc 4:6 to yield the
product as a yellowish solid. Yield: 57% (10 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.37 (DCM/MeOH 95:5).</p><p>
<sup>1</sup>H NMR (700
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.11 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.77 (s, 1H), 7.41 (s, 1H), 7.20 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.17 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H),
7.02 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 4.81 (s, 1H), 2.73 (dt, <italic toggle="yes">J</italic> = 12.7, 7.5 Hz, 2H), 2.62&#8211;2.58 (m, 1H), 2.37 (t, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 1.34 (d, <italic toggle="yes">J</italic> = 22.8 Hz,
6H), 1.07 (d, <italic toggle="yes">J</italic> = 6.1 Hz, 3H). <sup>13</sup>C NMR
(176 MHz, DMSO) &#948;: 173.4, 170.6, 141.9, 140.1, 127.1, 123.5,
121.8, 116.2, 72.4, 43.1, 42.1, 32.0, 28.1, 22.3, 17.2.</p><p>[&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;178 (<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + Na]<sup>+</sup> C<sub>15</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup>: 315.12455; found: 315.11267.</p></sec><sec id="sec4.1.10"><label>4.1.10</label><title>((<italic toggle="yes">S</italic>)-3-((<italic toggle="yes">R</italic>)-2-Carbamoyl-3,3-dimethylindolin-1-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
((<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14a</bold>)</title><p>According to procedure C, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>13a</bold> (65 mg, 0.11 mmol) was dissolved in DCM/TFA
1:1 (4 mL/4 mL) and the reaction was stirred overnight at room temperature.
The mixture was washed with NaHCO<sub>3</sub> and extracted with DCM.
Then, the solvent was evaporated under vacuum and the reaction was
purified by chromatography on silica gel with hexane/EtOAc (6:4) to
yield the product as a yellowish solid. Yield:80% (29 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.18 (H/E 4:6).</p><p>
<sup>1</sup>H NMR
(700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.05 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.69 (s, 1H), 7.29 (s, 1H), 7.19&#8211;7.14
(m, 2H), 7.01 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 4.51 (s, 1H),
3.02 (dd, <italic toggle="yes">J</italic> = 13.2, 5.6 Hz, 1H), 2.96 (dd, <italic toggle="yes">J</italic> = 13.2, 8.3 Hz, 1H), 2.67 (dq, <italic toggle="yes">J</italic> = 13.7,
6.8 Hz, 1H), 2.30 (s, 3H), 1.33 (s, 3H), 1.28 (s, 3H), 1.20 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 195.6, 173.4, 170.6, 142.4, 140.4,
127.7, 124.1, 122.2, 116.6, 72.3, 43.6, 39.1, 32.30, 31.7, 31.0, 22.5,
18.2.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M
+ H]<sup>+</sup> C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S<sup>+</sup>: 335.14; found: 335.14.</p></sec><sec id="sec4.1.11"><label>4.1.11</label><title>(<italic toggle="yes">R</italic>)-1-((<italic toggle="yes">S</italic>)-3-Mercapto-2-methylpropanoyl)-3,3-dimethylindoline-2-carboxamide
(<bold>6b</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14a</bold> (29 mg, 0.09 mmol)
was dissolved in THF/NaOH (1:3, 0.5 mL/1.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with hexane/EtOAc 4:6 to yield the product as a yellowish solid.
Yield: 33% (8.6 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.23 (H/E 2:8).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.07 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.77 (s, 1H),
7.41 (s, 1H), 7.18 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.17&#8211;7.14
(m, 1H), 7.03&#8211;7.00 (m, 1H), 4.57 (s, 1H), 2.76 (dt, <italic toggle="yes">J</italic> = 13.6, 7.0 Hz, 2H), 2.61&#8211;2.58 (m, 1H), 2.16&#8211;2.12
(m, 1H), 1.32 (d, <italic toggle="yes">J</italic> = 37.0 Hz, 6H), 1.20 (d, <italic toggle="yes">J</italic> = 6.7 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 173.2, 170.5, 142.0, 139.9, 127.2,
123.6, 116.1, 71.9, 43.2, 42.2, 31.9, 30.7, 26.8, 22.1, 17.1.</p><p>[&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;52.64 (<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>15</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup>: 293.12; found: 293.13.</p></sec><sec id="sec4.1.12"><label>4.1.12</label><title>((2<italic toggle="yes">S</italic>)-3-(3,3-Diethyl-2-(tritylcarbamoyl)&#173;indolin-1-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
(<bold>13b</bold>)</title><p>According to general procedure A, a mixture
of 3,3-diethyl-3<italic toggle="yes">H</italic>-indole <bold>10b</bold>, (100 mg,
0.69 mmol), 3-(acetylthio)-2-methylpropanoic acid <bold>12</bold> (70
&#956;, 0.76 mmol), and trityl isocyanide <bold>11</bold> (205 mg,
0.76 mmol) was dissolved in DCM (5 mL) in a sealed tube at 50 &#176;C
for 30 h. The crude product was purified by chromatography on silica
gel with hexane/EtOAc (85:15) to yield the diastereomeric mixture.
The racemic products were subjected to HPLC with MeOH/H<sub>2</sub>O (85:15) as the eluent (flow rate 3.00 mL/min) to obtain pure diastereomers.
Total yield: 47% (dr 1:1).</p><p>
<bold>(</bold>
<italic toggle="yes">
<bold>S</bold>
</italic>,<italic toggle="yes">
<bold>S&#8242;</bold>
</italic>
<bold>)-13b</bold>. Orange solid; <italic toggle="yes">R</italic>
<sub>f</sub> = 0.4 (H/E 7:3). <sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
9.01 (s, 1H), 7.93&#8211;7.88 (m, 1H), 7.24 (m, 16H), 6.98&#8211;6.91
(m, 3H), 5.07 (d, <italic toggle="yes">J</italic> = 8.3 Hz, 1H), 3.18 (dd, <italic toggle="yes">J</italic> = 9.4, 5.2 Hz, 2H), 3.09 (d, <italic toggle="yes">J</italic> = 7.0
Hz, 1H), 2.20 (dd, <italic toggle="yes">J</italic> = 31.3, 9.1 Hz, 4H), 1.34&#8211;1.22
(m, 6H), 0.74 (dd, <italic toggle="yes">J</italic> = 33.6, 7.4 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 195.7,
172.8, 168.0, 144.8 (2), 144.5 (2), 129.1 (6 C), 128.8 (6 C), 127.9
(3 C), 127.7, 126.9, 126.8, 123.5, 117.2, 70.2, 70.1, 51.9, 31.5,
31.0, 29.8, 21.8, 18.5, 17.8, 10.0, 7.7.</p><p>tR HPLC: 20.83 min.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>38</sub>H<sub>40</sub>N<sub>2</sub>O<sub>3</sub>S<sup>+</sup> 605.27596; found: 605.28387.</p><p>
<bold>(</bold>
<italic toggle="yes">
<bold>S</bold>
</italic>,<italic toggle="yes">
<bold>R</bold>
</italic>
<bold>&#8242;)-13b</bold>. Orange solid; <italic toggle="yes">R</italic>
<sub>f</sub> = 0.4 (H/E 7:3). <sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
8.93 (s, 1H), 7.92 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 7.32&#8211;7.25
(m, 8H), 7.22 (m, 7H), 7.12&#8211;7.09
(t, 1H), 7.06 (d, <italic toggle="yes">J</italic> = 7.2 Hz, 1H), 6.97&#8211;6.93
(t, 1H), 5.19 (s, 1H), 3.06 (d, <italic toggle="yes">J</italic> = 6.5 Hz, 2H),
2.94 (dq, <italic toggle="yes">J</italic> = 13.9, 7.5, 6.7 Hz, 1H), 2.33 (s, 3H),
1.74 (tt, <italic toggle="yes">J</italic> = 14.1, 7.1 Hz, 2H), 1.56&#8211;1.49
(m, 2H), 0.93 (dd, <italic toggle="yes">J</italic> = 16.9, 9.6 Hz, 4H), 0.67 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 199.7 172.4, 168.5, 144.6 (4), 129.15,
128.79 (6), 128.1 (6), 127.8 (3), 127.1, 123.6, 123.5, 117.2, 71.4,
70.42, 52.2, 32.9, 31.0, 30.7, 23.4, 17.1, 10.2, 8.1.</p><p>tR HPLC:
17.86 min.</p></sec><sec id="sec4.1.13"><label>4.1.13</label><title>((<italic toggle="yes">S</italic>)-3-((<italic toggle="yes">S</italic>)-2-Carbamoyl-3,3-diethylindolin-1-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
((<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold>)</title><p>According to procedure C, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>13b</bold> (100 mg, 0.18 mmol) was dissolved in DCM/TFA
1:1 (4 mL/4 mL) and the reaction mixture was stirred overnight at
room temperature. The mixture was washed with NaHCO<sub>3</sub> and
extracted with DCM. Then, the solvent was evaporated under vacuum
and the reaction was purified by chromatography on silica gel with
hexane/EtOAc (6:4) to yield the product as a yellowish solid. Yield:
86% (56 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.28 (H/E 6:4).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; 8.10 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 7.79 (s, 1H), 7.43
(s, 1H), 7.16 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.12 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.02 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 1H),
4.64 (s, 1H), 3.01 (d, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 2.81 (q, <italic toggle="yes">J</italic> = 6.6 Hz, 1H), 2.31 (s, 3H), 1.93 (dq, <italic toggle="yes">J</italic> = 14.4, 6.9 Hz, 1H), 1.71 (dt, <italic toggle="yes">J</italic> = 14.6, 7.0 Hz,
1H), 1.62 (ddt, <italic toggle="yes">J</italic> = 20.5, 13.7, 6.8 Hz, 2H), 1.09
(d, <italic toggle="yes">J</italic> = 6.3 Hz, 3H), 0.92 (t, <italic toggle="yes">J</italic> =
7.3 Hz, 3H), 0.68 (t, <italic toggle="yes">J</italic> = 7.1 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 194.9,
172.9, 170.6, 143.0, 136.9, 127.2, 123.3, 123.2, 116.3, 70.4, 50.6,
38.4, 33.2, 32.6, 30.5, 25.4, 17.3, 9.3, 7.8.</p></sec><sec id="sec4.1.14"><label>4.1.14</label><title>(<italic toggle="yes">S</italic>)-3,3-Diethyl-1-((<italic toggle="yes">S</italic>)-3-mercapto-2-methylpropanoyl)&#173;indoline-2-carboxamide
(<bold>6c</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold> (48 mg, 0.13 mmol)
was dissolved in THF/NaOH (1:3, 0.5 mL/1.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with hexane/EtOAc 1:1 to yield the product as a yellowish solid.
Yield: 32% (8.6 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.41 (H/E 4:6).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.12 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.77 (s, 1H),
7.47 (s, 1H), 7.16 (t, <italic toggle="yes">J</italic> = 7.7 Hz, 1H), 7.11 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.01 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 1H),
4.82 (s, 1H), 2.83 (dq, <italic toggle="yes">J</italic> = 12.8, 6.4 Hz, 1H), 2.70
(dt, <italic toggle="yes">J</italic> = 12.7, 9.0 Hz, 1H), 2.58 (ddd, <italic toggle="yes">J</italic> = 12.9, 7.5, 4.6 Hz, 1H), 2.32 (t, <italic toggle="yes">J</italic> = 8.3 Hz,
1H), 1.94 (dt, <italic toggle="yes">J</italic> = 14.6, 7.3 Hz, 1H), 1.70 (dq, <italic toggle="yes">J</italic> = 14.7, 7.3 Hz, 1H), 1.64 (q, <italic toggle="yes">J</italic> = 7.2
Hz, 2H), 1.06 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 3H), 0.96 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 3H), 0.68 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;:
173.4, 170.8, 143.1, 137.2, 123.3, 123.0, 116.3, 70.6, 50.6, 42.1,
32.8, 30.7, 28.1, 25.1, 17.5, 9.4, 7.9.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>17</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup>: 321.16; found: 321.16.</p></sec><sec id="sec4.1.15"><label>4.1.15</label><title>((<italic toggle="yes">S</italic>)-3-((<italic toggle="yes">R</italic>)-2-Carbamoyl-3,3-diethylindolin-1-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
((<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold>)</title><p>According to procedure C, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>13b</bold> (95 mg, 0.17 mmol) was dissolved in DCM/TFA
1:1 (4 mL/4 mL) and the reaction was stirred overnight at room temperature.
The mixture was washed with NaHCO<sub>3</sub> and extracted with DCM.
Then, the solvent was evaporated under vacuum and the reaction was
purified by chromatography on silica gel with hexane/EtOAc (6:4) to
yield the product as a yellowish solid. Yield: 65% (35 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.28 (H/E 6:4).</p><p>
<sup>1</sup>H NMR
(700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.12 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.78 (s, 1H), 7.39 (s, 1H), 7.23 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.17 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H),
7.07 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 4.61 (s, 1H), 3.08 (dd, <italic toggle="yes">J</italic> = 13.1, 5.5 Hz, 1H), 3.02 (dd, <italic toggle="yes">J</italic> = 13.2,
8.4 Hz, 1H), 2.82 (dq, <italic toggle="yes">J</italic> = 13.6, 6.7 Hz, 1H), 2.00
(tt, <italic toggle="yes">J</italic> = 10.8, 5.5 Hz, 1H), 1.76&#8211;1.67 (m,
2H), 1.59 (dq, <italic toggle="yes">J</italic> = 14.5, 7.3 Hz, 1H), 1.25 (d, <italic toggle="yes">J</italic> = 6.8 Hz, 3H), 1.03 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 3H),
0.71 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H). <sup>13</sup>C NMR (176
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 195.6, 173.2, 170.7,
143.4, 137.6, 128.2, 123.8, 123.6 116.7, 70.8, 51.0, 38.9, 32.8, 31.8,
30.9, 24.8, 18.2, 9.8, 8.2.</p></sec><sec id="sec4.1.16"><label>4.1.16</label><title>(<italic toggle="yes">R</italic>)-3,3-Diethyl-1-((<italic toggle="yes">S</italic>)-3-mercapto-2-methylpropanoyl)&#173;indoline-2-carboxamide
(<bold>6d</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold> (35 mg, 0.10 mmol)
was dissolved in THF/NaOH (1:3, 0.5 mL/1.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with hexane/EtOAc 1:1 to yield the product as a yellow solid.
Yield: 21% (9 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.41 (H/E 4:6).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.08 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 7.79 (s, 1H),
7.45 (s, 1H), 7.16 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.11 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.01 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 1H),
4.60 (s, 1H), 2.75 (dt, <italic toggle="yes">J</italic> = 13.6, 7.2 Hz, 1H), 2.69
(dq, <italic toggle="yes">J</italic> = 12.7, 6.2 Hz, 1H), 2.47 (dd, <italic toggle="yes">J</italic> = 13.2, 7.2 Hz, 1H), 2.12 (t, <italic toggle="yes">J</italic> = 8.1 Hz, 1H),
1.95 (dt, <italic toggle="yes">J</italic> = 14.4, 7.2 Hz, 1H), 1.66 (ddt, <italic toggle="yes">J</italic> = 27.6, 14.0, 7.1 Hz, 3H), 1.56 (dq, <italic toggle="yes">J</italic> = 14.3, 7.3 Hz, 1H), 1.19 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 3H),
0.97 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H), 0.65 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 173.5, 171.2, 143.5, 137.6, 127.6, 123.8,
123.5, 116.8, 70.9, 51.0, 42.5, 32.9, 27.5, 25.0, 17.5, 9.8, 8.2.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>17</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup>: 321.16; found: 321.16.</p></sec><sec id="sec4.1.17"><label>4.1.17</label><title>((2<italic toggle="yes">S</italic>)-2-Methyl-3-oxo-3-(2&#8242;-(tritylcarbamoyl)&#173;spiro&#173;[cyclohexane-1,3&#8242;-indolin]-1&#8242;-yl)&#173;propyl)&#173;ethanethioate
(<bold>13c</bold>)</title><p>Chemical procedures and spectral data
for (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>13c</bold>, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>13c</bold> are reported in our previously published paper.<xref rid="ref39" ref-type="bibr"/>
</p></sec><sec id="sec4.1.18"><label>4.1.18</label><title>((<italic toggle="yes">S</italic>)-3-((<italic toggle="yes">S</italic>)-2&#8242;-Carbamoylspiro&#173;[cyclohexane-1,3&#8242;-indolin]-1&#8242;-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
((<italic toggle="yes">S</italic>,<italic toggle="yes">S&#8242;</italic>)-<bold>14c</bold>)</title><p>According to procedure C, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>13c</bold> (215 mg, 0.34 mmol) was dissolved in DCM/TFA
1:1 (4.5 mL/4.5 mL) and the reaction mixture was stirred overnight
at room temperature. The mixture was washed with NaHCO<sub>3</sub> and extracted with DCM. Then, the solvent was evaporated under vacuum,
and the reaction was purified by chromatography on silica gel with
hexane/EtOAc (6:4) to yield the product as a yellow solid. Yield:
78% (95 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.19 (H/E 6:4).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>)
&#948; 8.21 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 8.06 (s, 1H), 7.59
(s, 1H), 7.38 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.33 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.20 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 1H),
5.01 (s, 1H), 3.28&#8211;3.23 (m, 1H), 3.20 (q, <italic toggle="yes">J</italic> = 9.4, 8.0 Hz, 2H), 2.50 (s, 3H), 1.84 (m, 8H), 1.56&#8211;1.46
(m, 2H), 1.29 (d, <italic toggle="yes">J</italic> = 6.0 Hz, 3H). <sup>13</sup>C
NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 194.8,
172.7, 170.1, 142.1, 140.8, 127.0, 123.6, 121.9, 116.5, 69.4, 47.4,
37.9, 32.5, 30.5, 29.5, 25.1, 22.7, 21.9, 17.4 (2).</p></sec><sec id="sec4.1.19"><label>4.1.19</label><title>(<italic toggle="yes">S</italic>)-1&#8242;-((<italic toggle="yes">S</italic>)-3-Mercapto-2-methylpropanoyl)&#173;spiro&#173;[cyclohexane-1,3&#8242;-indoline]-2&#8242;-carboxamide
(<bold>6e</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14c</bold> (35 mg, 0.10 mmol)
was dissolved in THF/NaOH (1:3, 0.5 mL/1.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with hexane/EtOAc 6:4 to yield the product as a yellow solid.
Yield: 38% (25 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.56 (H/E 4:6).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.11 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 7.93 (s, 1H),
7.50 (s, 1H), 7.26 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.20 (t, <italic toggle="yes">J</italic> = 7.7 Hz, 1H), 7.06 (t, <italic toggle="yes">J</italic> = 7.7 Hz, 1H),
5.05 (s, 1H), 3.11&#8211;3.05 (m, 1H), 2.76 (dt, <italic toggle="yes">J</italic> = 13.0, 9.3 Hz, 1H), 2.67 (ddd, <italic toggle="yes">J</italic> = 12.9, 7.8,
5.0 Hz, 1H), 2.42 (t, <italic toggle="yes">J</italic> = 8.4 Hz, 1H), 1.98&#8211;1.91
(m, 1H), 1.86&#8211;1.80 (m, 2H), 1.79&#8211;1.70 (m, 4H), 1.62
(dt, <italic toggle="yes">J</italic> = 13.1, 3.5 Hz, 2H), 1.41&#8211;1.34 (m,
1H), 1.14 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 3H). <sup>13</sup>C NMR
(176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 173.7, 170.8,
142.7, 141.4, 127.4, 123.9, 122.4, 116.9, 69.8, 47.9, 42.1, 30.1,
28.5, 25.5, 23.3, 22.4, 18.0 (2).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>18</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup>: 333.15987; found:
333.16309.</p></sec><sec id="sec4.1.20"><label>4.1.20</label><title>((<italic toggle="yes">S</italic>)-3-((<italic toggle="yes">R</italic>)-2&#8242;-Carbamoylspiro&#173;[cyclohexane-1,3&#8242;-indolin]-1&#8242;-yl)-2-methyl-3-oxopropyl)&#173;ethanethioate
((<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14c</bold>)</title><p>According to procedure C, (<italic toggle="yes">S</italic>,<italic toggle="yes">R&#8242;</italic>)-<bold>13c</bold> (200 mg, 0.325 mmol) was dissolved in DCM/TFA
1:1 (4.5 mL/4.5 mL) and the reaction was stirred overnight at room
temperature. The mixture was washed with NaHCO<sub>3</sub> and extracted
with DCM. Then, the solvent was evaporated under vacuum and the reaction
was purified by chromatography on silica gel with hexane/EtOAc (6:4)
to yield the product as a yellowish solid. Yield: 60% (72 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.19 (H/E 6:4).</p><p>
<sup>1</sup>H NMR
(700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.99 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 7.87 (s, 1H), 7.30 (s, 1H), 7.17 (d, <italic toggle="yes">J</italic> = 7.4 Hz, 1H), 7.13 (t, <italic toggle="yes">J</italic> = 7.7 Hz, 1H),
6.99 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 1H), 4.72 (s, 1H), 3.03 (dd, <italic toggle="yes">J</italic> = 13.2, 5.5 Hz, 1H), 2.98 (dd, <italic toggle="yes">J</italic> = 13.1,
8.6 Hz, 1H), 2.89 (dq, <italic toggle="yes">J</italic> = 13.7, 6.8 Hz, 1H), 2.31
(s, 3H), 1.92&#8211;1.79 (m, 2H), 1.74 (d, <italic toggle="yes">J</italic> = 12.6
Hz, 2H), 1.70&#8211;1.61 (m, 4H), 1.55 (t, <italic toggle="yes">J</italic> = 14.2
Hz, 2H), 1.19 (d, <italic toggle="yes">J</italic> = 6.8 Hz, 3H). <sup>13</sup>C
NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 195.5,
173.1, 170.2, 142.7, 141.2, 127.4, 124.0, 122.3, 116.8, 69.0, 47.8,
39.2, 31.7, 30.9, 29.9, 25.6, 23.2, 22.2, 18.6 (2).</p></sec><sec id="sec4.1.21"><label>4.1.21</label><title>(<italic toggle="yes">R</italic>)-1&#8242;-((<italic toggle="yes">S</italic>)-3-Mercapto-2-methylpropanoyl)&#173;spiro&#173;[cyclohexane-1,3&#8242;-indoline]-2&#8242;-carboxamide
(<bold>6f</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14c</bold> (72 mg, 0.20 mmol)
was dissolved in THF/NaOH (1:3, 1.2 mL/3.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with hexane/EtOAc 6:4 to yield the product as a yellowish solid.
Yield: 33% (20 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.56 (H/E 4:6).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.08 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.06 (d, <italic toggle="yes">J</italic> = 8.0 Hz, 1H), 8.03 (s, 1H), 8.01 (s, 1H), 7.52 (s, 1H),
7.48 (s, 1H), 7.24 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 2H), 7.19 (t, <italic toggle="yes">J</italic> = 7.7 Hz, 2H), 7.06 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 2H),
4.85 (s, 1H), 4.83 (s, 1H), 3.16 (dd, <italic toggle="yes">J</italic> = 12.8, 7.7
Hz, 1H), 3.14&#8211;3.08 (m, 1H), 2.90 (dq, <italic toggle="yes">J</italic> =
13.6, 6.8 Hz, 2H), 2.87&#8211;2.80 (m, 2H), 2.55&#8211;2.51 (m,
1H), 2.19 (t, <italic toggle="yes">J</italic> = 8.2 Hz, 1H), 1.94 (dt, <italic toggle="yes">J</italic> = 15.7, 8.4 Hz, 2H), 1.87&#8211;1.78 (m, 5H), 1.79&#8211;1.68
(m, 8H), 1.66&#8211;1.55 (m, 5H), 1.30 (d, <italic toggle="yes">J</italic> = 6.5
Hz, 3H), 1.26 (d, <italic toggle="yes">J</italic> = 6.7 Hz, 3H). <sup>13</sup>C
NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 173.0,
170.1, 142.2, 140.7, 127.0, 123.5, 121.9, 116.4, 68.7, 47.4, 42.1,
29.5, 26.9, 25.1, 22.8, 21.9, 18.0, 17.5.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>18</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S<sup>+</sup>: 333.16; found: 333.16.</p></sec><sec id="sec4.1.22"><label>4.1.22</label><title>Ethyl (1-((<italic toggle="yes">S</italic>)-3-(Acetylthio)-2-methylpropanoyl)-3,3-dimethylindoline-2-carbonyl)&#173;glycinate
((<italic toggle="yes">S,S</italic>)<italic toggle="yes">-</italic>16a, (<italic toggle="yes">S,R</italic>)-16a)</title><p>According to general procedure A, a mixture of 3,3-dimethyl-3<italic toggle="yes">H</italic>-indole <bold>10a</bold>, (150 mg, 1.03 mmol), 3-(acetylthio)-2-methylpropanoic
acid <bold>12</bold> (103 &#956;L, 1.33 mmol), and ethyl isocyanoacetate <bold>15</bold> (124 &#956;L, 1.33 mmol) was dissolved in DCM (5 mL) in
a sealed tube at 50 &#176;C for 30 h. The crude product was purified
by chromatography on silica gel with a hexane/EtOAc (85:15) to yield
the diastereomeric mixture. The racemic products were subjected to
HPLC with MeOH/H<sub>2</sub>O (65:35) as the eluent (flow rate 3.00
mL/min) to provide the pure diastereomers. Total yield: 32% (dr 1:1).</p><p>tR HPLC: 22.35; tR HPLC: 24.36.</p><p>
<sup>1</sup>H NMR (600 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.78 (d, <italic toggle="yes">J</italic> = 26.8 Hz, 2H), 8.07 (t, <italic toggle="yes">J</italic> = 8.8 Hz, 2H), 7.22&#8211;7.14
(m, 4H), 7.07&#8211;6.99
(m, 2H), 4.72 (s, 1H), 4.63 (s, 1H), 4.11&#8211;4.07 (m, 4H), 3.87,(m,
4H), 3.04 (m, 3H), 2.96 (m, 3H), 2.34 (s, 6H), 1.36&#8211;1.29 (m,
12H), 1.20&#8211;1.18 (m, 6H), 1.12 (d, <italic toggle="yes">J</italic> = 7.1
Hz, 6H).</p></sec><sec id="sec4.1.23"><label>4.1.23</label><title>((<italic toggle="yes">S</italic>)-1-((<italic toggle="yes">S</italic>)-3-Mercapto-2-methylpropanoyl)-3,3-dimethylindoline-2-carbonyl)&#173;glycine
(<bold>7a</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>16a</bold> (75 mg, 0.18 mmol)
was dissolved in THF/NaOH (1:3, 1.2 mL/3.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with DCM/MeOH 9:1 to yield the product as a white solid. Yield:
37% (23 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.37 (DCM/MeOH 8:2 +
formic acid).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 10.22 (s, 1H), 8.59 (s, 1H), 8.10 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 1H), 7.20&#8211;7.14 (m, 2H), 7.02 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 4.96 (s, 1H), 3.78&#8211;3.69 (m, 2H),
2.83&#8211;2.76 (m, 1H), 2.69 (dt, <italic toggle="yes">J</italic> = 18.3, 9.1
Hz, 1H), 2.58 (dt, <italic toggle="yes">J</italic> = 13.0, 6.7 Hz, 1H), 2.40 (t, <italic toggle="yes">J</italic> = 8.2 Hz, 1H), 1.32 (s, 3H), 1.24 (s, 3H), 1.02 (d, <italic toggle="yes">J</italic> = 6.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 174.0, 168.9, 168.9, 142.42, 140.81,
127.60, 124.03, 122.25, 116.74, 72.74, 44.06, 42.47, 32.41, 29.46,
28.77, 22.56, 17.79.</p><p>[&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;89.34
(<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S<sup>+</sup>: 351.13003; found: 351.13635.</p></sec><sec id="sec4.1.24"><label>4.1.24</label><title>((<italic toggle="yes">R</italic>)-1-((<italic toggle="yes">S</italic>)-3-Mercapto-2-methylpropanoyl)-3,3-dimethylindoline-2-carbonyl)&#173;glycine
(<bold>7b</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>16a</bold> (61 mg, 0.15 mmol)
was dissolved in THF/NaOH (1:3, 1.0 mL/3.0 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with DCM/MeOH 9:1 to yield the product as a white solid. Yield:
98% (49 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.27 (DCM/MeOH 8:2 +
formic acid).</p><p>
<sup>1</sup>H NMR (700 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 10.28 (s, 1H), 8.50 (s, 1H), 8.15&#8211;8.11
(m, 1H), 7.22 (dt, <italic toggle="yes">J</italic> = 14.6, 7.1 Hz, 2H), 7.10&#8211;7.05
(m, 1H), 4.79 (s, 1H), 3.79&#8211;3.67 (m, 2H), 3.06 (dd, <italic toggle="yes">J</italic> = 13.1, 6.4 Hz, 1H), 2.84&#8211;2.75 (m, 2H), 2.73 (dt, <italic toggle="yes">J</italic> = 13.6, 7.0 Hz, 2H), 1.37 (t, <italic toggle="yes">J</italic> = 7.6
Hz, 6H), 1.31&#8211;1.26 (m, 3H). <sup>13</sup>C NMR (176 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 174.0, 168.5, 168.5, 142.4, 140.5,
127.6, 124.0, 122.2, 116.6, 72.4, 55.4, 49.0, 42.7, 32.3, 27.5, 22.4,
17.5.</p><p>[&#945;]<sub>D</sub>
<sup>20</sup> = &#8722;26.32 (<italic toggle="yes">c</italic> 0.3, MeOH).</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S<sup>+</sup>: 351.13004; found: 351.13678.</p></sec><sec id="sec4.1.25"><label>4.1.25</label><title>Ethyl (1-((<italic toggle="yes">S</italic>)-3-(Acetylthio)-2-methylpropanoyl)-3,3-diethylindoline-2-carbonyl)&#173;glycinate
(<bold>16b</bold>)</title><p>According to general procedure A, a mixture
of 3,3-diethyl-3<italic toggle="yes">H</italic>-indole <bold>10b</bold>, (320 mg,
1.85 mmol), 3-(acetylthio)-2-methylpropanoic acid <bold>12</bold> (186
&#956;L, 2.04 mmol), and ethyl isocyanoacetate <bold>15</bold> (223
&#956;L, 2.04 mmol) was dissolved in DCM (5 mL) in a sealed tube
at 50 &#176;C for 30 h. The crude product was purified by chromatography
on silica gel with hexane/EtOAc (9:1) to yield the diastereomeric
mixture. The racemic products were subjected to HPLC with MeOH/H<sub>2</sub>O (85:15) as the eluent (flow rate 3.00 mL/min) to obtain
the pure diastereomers. Total yield: 23% (dr 1:1).</p><p>
<bold>(</bold>
<italic toggle="yes">
<bold>S</bold>
</italic>,<italic toggle="yes">
<bold>S</bold>
</italic>
<bold>)-16b</bold>. Yellow solid; <italic toggle="yes">R</italic>
<sub>f</sub> = 0.28
(H/E 7:3).</p><p>
<sup>1</sup>H NMR (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.75 (s, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.22&#8211;7.09
(m, 2H), 7.02 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 4.68 (s, 1H),
4.09 (q, <italic toggle="yes">J</italic> = 7.1 Hz, 2H), 3.91 (dd, <italic toggle="yes">J</italic> = 17.4, 5.5 Hz, 1H), 3.78 (dd, <italic toggle="yes">J</italic> = 17.4, 5.6 Hz,
1H), 2.97 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 2H), 2.74 (q, <italic toggle="yes">J</italic> = 6.7 Hz, 1H), 2.30 (s, 3H), 1.61 (ddq, <italic toggle="yes">J</italic> = 49.5,
14.6, 6.8 Hz, 4H), 1.19 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 6H), 0.94
(t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H), 0.66 (t, <italic toggle="yes">J</italic> =
7.2 Hz, 3H). <sup>13</sup>C <sup>13</sup>C NMR (101 MHz, DMSO) &#948;
195.3, 172.8, 169.2, 168.9, 142.8, 137.1, 127.2, 123.3, 123.2, 116.3,
70.2, 60.5, 50.9, 40.8, 38.2, 32.1, 31.4, 30.4, 24.2, 17.4, 14.0,
9.23, 7.7.</p><p>
<bold>(</bold>
<italic toggle="yes">
<bold>S</bold>
</italic>,<italic toggle="yes">
<bold>R</bold>
</italic>
<bold>)-16b</bold>. Yellow solid; <italic toggle="yes">R</italic>
<sub>f</sub> = 0.28 (H/E 7:3).</p><p>
<sup>1</sup>H NMR
(400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.79 (s, 1H),
8.09 (d, <italic toggle="yes">J</italic> = 8.1 Hz, 1H),
7.18 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.13 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 1H), 7.03 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 4.78 (s,
1H), 4.09 (dtt, <italic toggle="yes">J</italic> = 10.8, 7.3, 3.7 Hz, 2H), 3.86
(t, <italic toggle="yes">J</italic> = 5.4 Hz, 2H), 3.01 (d, <italic toggle="yes">J</italic> =
6.8 Hz, 2H), 2.85 (dq, <italic toggle="yes">J</italic> = 13.6, 6.5 Hz, 1H), 2.32
(s, 3H), 1.91 (dq, <italic toggle="yes">J</italic> = 14.9, 7.4 Hz, 1H), 1.71&#8211;1.59
(m, 3H), 1.18 (t, <italic toggle="yes">J</italic> = 7.1 Hz, 3H), 1.05 (d, <italic toggle="yes">J</italic> = 6.5 Hz, 3H), 0.89 (t, <italic toggle="yes">J</italic> = 7.4 Hz, 3H),
0.70 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101
MHz, DMSO) &#948;: 195.3, 173.4, 169.8, 169.6, 143.3, 137.5, 127.7,
123.8, 123.8, 117.0, 70.9, 61.0, 51.5, 41.3, 38.7, 33.2, 33.1, 31.0,
25.3, 17.8, 14.5, 9.7, 8.3.</p></sec><sec id="sec4.1.26"><label>4.1.26</label><title>((<italic toggle="yes">S</italic>)-3,3-Diethyl-1-((S)-3-mercapto-2-methylpropanoyl)&#173;indoline-2-carbonyl)&#173;glycine
(<bold>7c</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>16b</bold> (50 mg, 0.11 mmol)
was dissolved in THF/NaOH (1:3, 1.5 mL/4.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with DCM/MeOH 9:1 to yield the product as a yellow solid. Yield:
95% (40 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.32 (DCM/MeOH 8:2 +
formic acid).</p><p>
<sup>1</sup>H NMR (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.48 (s, 1H), 8.12 (d, <italic toggle="yes">J</italic> =
7.9 Hz, 1H), 7.17 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 7.11 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 1H), 7.02 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 1H),
5.00 (s, 1H), 3.71 (s, 2H), 2.69&#8211;2.62 (m, 1H), 2.57 (dd, <italic toggle="yes">J</italic> = 12.7, 7.3 Hz, 1H), 2.44&#8211;2.30 (m, 1H), 1.66 (tt, <italic toggle="yes">J</italic> = 14.4, 7.4 Hz, 4H), 1.01 (d, <italic toggle="yes">J</italic> = 6.4
Hz, 3H), 0.91 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 3H), 0.69 (t, <italic toggle="yes">J</italic> = 7.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 174.0, 169.2, 162.7, 143.4, 137.8,
127.5, 123.8, 123.5, 116.8, 71.01, 51.3, 36.7, 36.2, 32.9, 31.2, 25.2,
18.1, 9.6, 8.3.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc. [M + H]<sup>+</sup> C<sub>19</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub>S<sup>+</sup>: 379.16; found: 379.07.</p></sec><sec id="sec4.1.27"><label>4.1.27</label><title>((<italic toggle="yes">R</italic>)-3,3-Diethyl-1-((<italic toggle="yes">S</italic>)-3-mercapto-2-methylpropanoyl)&#173;indoline-2-carbonyl)&#173;glycine
(<bold>7d</bold>)</title><p>According to procedure D, (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>16b</bold> (45 mg, 0.11 mmol)
was dissolved in THF/NaOH (1:3, 1.5 mL/4.5 mL) and the reaction was
stirred for 2 h at room temperature. The mixture was quenched with
2 N HCl and extracted with ethyl acetate. Then, the solvent was evaporated
under vacuum and the reaction was purified by chromatography on silica
gel with DCM/MeOH 9:1 to yield the product as a yellow solid. Yield:
97% (37 mg). <italic toggle="yes">R</italic>
<sub>f</sub> = 0.32 (DCM/MeOH 8:2 +
formic acid).</p><p>
<sup>1</sup>H NMR (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.43 (s, 1H), 8.07 (d, <italic toggle="yes">J</italic> =
7.6 Hz, 1H), 7.20&#8211;7.13 (m, 1H), 7.11 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 1H), 7.02 (d, <italic toggle="yes">J</italic> = 7.1 Hz, 1H), 4.82 (s,
1H), 3.73 (s, 2H), 2.99 (d, <italic toggle="yes">J</italic> = 9.6 Hz, 1H), 2.79&#8211;2.64
(m, 2H), 1.69&#8211;1.61 (m, 2H), 1.57 (dd, <italic toggle="yes">J</italic> =
13.9, 7.6 Hz, 2H), 1.20 (s, 3H), 0.94 (s, 4H), 0.66 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;: 173.6, 169.4, 168.7, 143.4, 137.7, 127.5,
123.7, 123.5, 116.7, 70.8, 51.2, 32.7, 29.4, 27.6, 24.8, 22.5, 17.76,
9.72, 8.23.</p><p>MS (ESI) <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> calc.
[M + H]<sup>+</sup> C<sub>19</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub>S<sup>+</sup>: 379.16; found: 379.07.</p></sec><sec id="sec4.1.28"><label>4.1.28</label><title>Stereochemical Characterization of Compound <bold>14b</bold>
</title><p>The absolute stereochemistry of compound <bold>14b</bold> was investigated by a combination of experimental and
computational CD spectroscopy, in accordance with well-established
protocols.<xref rid="ref44" ref-type="bibr"/>
</p><p>A preliminary exploration
of the conformational space of (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold> and (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold> was achieved using the molecular mechanics
(MM) methods implemented in RDKit.<xref rid="ref45" ref-type="bibr"/> Conformers
were generated with the ETKDG algorithm,<xref rid="ref46" ref-type="bibr"/> using 2000 initial structures and 100 trial attempts. Energy minimization
was performed with the MMFF94s force field,<xref rid="ref47" ref-type="bibr"/> allowing up to 2000 iterations, and conformers were clustered based
on a 0.1 &#197; RMSD threshold (heavy atoms only).</p><p>Conformers
within a 20 kJ mol<sup>&#8211;1</sup> energy window
relative to the MM global minimum&#58872;80 for (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold>, 70 for (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold>&#58872;were subjected
to DFT geometry optimizations and vibrational frequency calculations,
which were carried out using the B97D3 functional,<xref rid="ref48" ref-type="bibr"/> the def2-TZVP basis set,<named-content content-type="bibref-group">
<xref rid="ref49" ref-type="bibr"/>,<xref rid="ref50" ref-type="bibr"/>
</named-content> the density
fitting approximation,<named-content content-type="bibref-group">
<xref rid="ref51" ref-type="bibr"/>,<xref rid="ref52" ref-type="bibr"/>
</named-content> and the IEFPCM solvent model
for methanol.<xref rid="ref53" ref-type="bibr"/> Conformers with imaginary
frequencies or redundant geometries (RMSD &lt; 0.01 &#197; for heavy
atoms) were excluded from further analysis.</p><p>Subsequent TDDFT
calculations were performed on the optimized geometries
using the PBE0-1/3 functional,<xref rid="ref54" ref-type="bibr"/> in combination
with the def2-TZVPD basis set<named-content content-type="bibref-group">
<xref rid="ref49" ref-type="bibr"/>,<xref rid="ref55" ref-type="bibr"/>,<xref rid="ref56" ref-type="bibr"/>
</named-content> and IEFPCM solvation for methanol. For each structure, excitation
energies (&#955;<sub>
<italic toggle="yes">j</italic>
</sub>), oscillator strengths
(<italic toggle="yes">f</italic>
<sub>
<italic toggle="yes">j</italic>
</sub>), and rotational
strengths in the dipole length representation (<italic toggle="yes">R</italic>
<sub>
<italic toggle="yes">j</italic>
</sub>) were computed for the lowest-energy 40
excited states.</p><p>The theoretical UV and CD spectra of <bold>14b</bold> stereoisomers
were generated by applying Gaussian broadening (&#916;&#963; = 0.3
eV) to the computed <italic toggle="yes">f</italic>
<sub>
<italic toggle="yes">j</italic>
</sub> and <italic toggle="yes">R</italic>
<sub>
<italic toggle="yes">j</italic>
</sub> values, summing
over all excited states, and averaging across conformers according
to their Boltzmann-weighted populations derived from relative SCF
energies (&#916;<italic toggle="yes">E</italic>
<sub>SCF</sub>); at this stage,
only conformers contributing cumulatively to more than 90% of the
total Boltzmann distribution were considered&#8211;11 for (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold>, 12 for (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold>. All DFT
and TDDFT calculations were performed using the Gaussian 16 software
package.<xref rid="ref57" ref-type="bibr"/> Full results are provided in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Tables S1&#8211;S5</ext-link> in the Supporting Information.</p><p>The experimental UV and CD spectra of (<italic toggle="yes">S</italic>,<italic toggle="yes">S</italic>&#8242;)-<bold>14b</bold> and (<italic toggle="yes">S</italic>,<italic toggle="yes">R</italic>&#8242;)-<bold>14b</bold> were acquired on a Jasco J-715
spectropolarimeter, employing a Suprasil quartz cell (Hellma Analytics)
with a 1 mm optical path length. Measurements were carried out on
0.1 mM solutions in methanol over the 350&#8211;200&#8239;nm spectral
range; a spectral bandwidth of 1&#8239;nm, a scanning speed of 50&#8239;nm
min<sup>&#8211;1</sup>, a data integration time of 2&#8239;s, a
data pitch of 1&#8239;nm, and an accumulation cycle of 3 scans were
used. The resulting spectra were solvent-corrected, converted to molar
units, and compared to the theoretical spectra of <bold>14b</bold> stereoisomers (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>).</p></sec></sec><sec id="sec4.2"><label>4.2</label><title>Biological Assays</title><sec id="sec4.2.1"><label>4.2.1</label><title>Enzyme
Assays</title><p>The inhibitory activity
of the compounds was determined using enzyme assays with recombinant
NDM-1, VIM-1, VIM-2, IMP-1, and IMP-7. These enzymes were produced
in <italic toggle="yes">E. coli</italic> and purified as previously
described.<named-content content-type="bibref-group">
<xref rid="ref43" ref-type="bibr"/>,<xref rid="ref58" ref-type="bibr"/>
</named-content> The fluorogenic substrate fluorocillin
was synthesized according to the procedure described by Rukavishnikov
et al.<xref rid="ref43" ref-type="bibr"/> The assays were performed in 96-well
format using black polystyrene plates (Corning, Corning, NY) at room
temperature, and the measurements were carried out on the Tecan spectrophotometer
Infinite F200 PRO (Tecan, M&#228;nnedorf, Switzerland). The protein
stock solutions were diluted in assay buffer (HEPES 50 mM, pH 7.5
containing 0.01%Triton X-100, buffer HX) to reach final concentrations
of VIM-1&#8211;4 nM, IMP-7&#8211;0.1 nM; NDM-1&#8211;3 nM. Subsequently,
89 &#956;L of the protein solution was mixed with 1 &#956;L of the
inhibitor diluted in DMSO (final DMSO concentration 1% at final assay
volume of 100 &#956;L) and incubated for 30 min. A 10 &#956;L substrate
solution in assay buffer (888 nM fluorocillin, HEPES 50 mM, pH 7.5;
0.01%Triton X-100) was added, and fluorescence increase (excitation
at 495 nm and emission at 525 nm) was measured for 30 cycles of 1
min each. Negative controls were measured in the absence of enzyme
(89 &#956;L of assay buffer), whereas the positive controls were
measured in the presence of enzyme and in the absence of inhibitors
(1 &#956;L of DMSO). Each measurement was performed in triplicate
in three independent experiments. IC<sub>50</sub> values were calculated
using data obtained from measurements with at least eight different
inhibitor concentrations, applying a sigmoidal dose&#8211;response
(variable slope with four parameters) equation using GraphPad Prism
5 (GraphPad Software, La Jolla, CA) software. In contrast, the inhibitory
activity was measured using a direct competition assay in which the
rate of hydrolysis of 150 &#956;M imipenem (as the reporter substrate,
prepared extemporaneously, Merck cat. No. PHR1796) in buffer HX was
measured in the absence and in the presence of various concentrations
of the inhibitor. First, these assays were performed at a final concentration
of the inhibitor in the reaction mixture of 50 &#956;M, without preincubation,
and the percentage of inhibition was computed as 100 &#215; (1 &#8211;
[<italic toggle="yes">v<sub>i</sub>
</italic>/<italic toggle="yes">v</italic>
<sub>0</sub>]),
where <italic toggle="yes">v<sub>i</sub>
</italic> and <italic toggle="yes">v</italic>
<sub>0</sub> are the rates of hydrolysis of the reporter substrate with and without
the inhibitor, respectively. For compounds showing a significant inhibitory
activity, the <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values
were determined using a competitive model of inhibition by measuring
the rate of hydrolysis in the presence of varying concentrations of
inhibitor, as previously described.<xref rid="ref58" ref-type="bibr"/> All
assays were performed in at least in triplicate. For inhibitors behaving
as inactivators (i.e., showing a measurable decrease of the rate of
hydrolysis of the reporter substrate during the reaction), the pseudo-first
order inactivation rate (<italic toggle="yes">k</italic>
<sub>inact</sub>) was measured
and data processed as previously described [doi: 10.1021/bi971056h],
by investigating the dependence of <italic toggle="yes">k</italic>
<sub>inact</sub> on the inhibitor concentration.</p><p>To assess the selectivity
of the compounds, their inhibitory activity on human angiotensin-converting
enzyme 1 (ACE-1) was performed using the ACE Activity Assay Kit (Sigma-Aldrich
cat. No. CS0002). Briefly, the hydrolysis rate of an internally quenched
fluorogenic substrate was determined in both the absence and presence
of 50 &#956;M inhibitor, in black 96-well plates (PerkinElmer Optiplate)
and an Envision multitechnology plate reader (PerkinElmer, Whaltam)
equipped with monochromators (excitation and emission wavelengths,
332 and 398 nm, respectively). Captopril (racemic mixture, <sc>d</sc>- and <sc>l</sc>-stereoisomers) was used as control in these experiments.</p></sec><sec id="sec4.2.2"><label>4.2.2</label><title>Microbiological Assays</title><p>
<italic toggle="yes">In vitro</italic> antimicrobial susceptibility testing was performed
according to established standards. The synergistic activity of the
compounds was investigated by measuring the minimal inhibitory concentrations
(MICs) of imipenem monohydrate (Sigma-Aldrich, Steinheim, Germany)
in the absence and presence of a fixed concentration (32 or 128 &#956;g/mL)
of the compounds on metallo-&#946;-lactamase-producing clinical isolates
using the broth microdilution method (Clinical and Laboratory Standards
Institute) (CLSI). The strains used in the study were described elsewhere.<xref rid="ref58" ref-type="bibr"/>
</p></sec><sec id="sec4.2.3"><label>4.2.3</label><title>Growth Inhibition Assay</title><p>A computerized
incubator (Tecan Infinite M200 pro, Crailsheim, Germany) was used
to obtain the growth curves over a time course. Optical density (OD<sub>600</sub>) was measured for evaluating bacterial (i.e., <italic toggle="yes">K. pneumoniae</italic> NDM-1, <italic toggle="yes">P. aeruginosa</italic> IMP-1, <italic toggle="yes">K. pneumoniae</italic> VIM-1) density
in suspension. Prior to each experiment, bacteria were cultured to
the exponential phase (OD<sub>600</sub> = 0.6&#8211;0.8) in cation-adjusted
Mueller Hinton broth (Becton Dickinson, Heidelberg, Germany). 5 &#956;L
of diluted bacterial suspension and 100 &#956;L of cation-adjusted
Mueller Hinton broth either with or without imipenem (Arcos Organics,
Schwerte, Germany) and/or the MBL inhibitor <bold>6d</bold> were added
into wells of a 96-well plate to give a final bacterial inoculum of
approximately 5 &#215; 10<sup>5</sup> CFU/mL. The temperature was
adjusted to 37 &#176;C. A permanent shaking speed of 450 rpm was used
and was only interrupted before OD<sub>600</sub> measurement. The
optical densities of samples were recorded online every 10 min for
24 h.</p></sec></sec><sec id="sec4.3"><label>4.3</label><title>Computational Studies</title><sec id="sec4.3.1"><label>4.3.1</label><title>Molecular Docking</title><p>The crystallographic
structures of NDM-1 in complex with <sc>d</sc>-captopril at 1.10 &#197;
resolution (PDB-ID: <ext-link xlink:href="5ZJ2" ext-link-type="PDB">5ZJ2</ext-link>),<xref rid="ref34" ref-type="bibr"/> VIM-1 in complex with (<bold>2</bold>M)-4&#8242;-methyl-2-(2<italic toggle="yes">H</italic>-tetrazol-5-yl)&#173;[1,1&#8242;-biphenyl]-3-sulfonamide
at 1.13 &#197; resolution (PDB-ID: <ext-link xlink:href="7UP2" ext-link-type="PDB">7UP2</ext-link>),<xref rid="ref59" ref-type="bibr"/> VIM-2
in complex with inhibitor MS19 at 1.60 &#197; resolution (PDB-ID: <ext-link xlink:href="6JN6" ext-link-type="PDB">6JN6</ext-link>),<xref rid="ref60" ref-type="bibr"/> and IMP-1 in complex with (3-(4-(<italic toggle="yes">p</italic>-tolyl)-1<italic toggle="yes">H</italic>-1,2,3-triazol-1-yl)&#173;benzyl)&#173;phosphonic acid (PDB-ID: <ext-link xlink:href="7YHA" ext-link-type="PDB">7YHA</ext-link>)<xref rid="ref61" ref-type="bibr"/> were retrieved from the Protein Data Bank (RCBS.org, PDB).<xref rid="ref62" ref-type="bibr"/> The structure of <italic toggle="yes">P. aeruginosa</italic> IMP-7 is not available in PDB, and it was generated by homology
modeling based on structural templates described in the literature
(PDB-ID: <ext-link xlink:href="7YHA" ext-link-type="PDB">7YHA</ext-link>).<xref rid="ref63" ref-type="bibr"/> The sequence of IMP-7 was retrieved
from UniProtKB<xref rid="ref64" ref-type="bibr"/> (ID: <ext-link ext-link-type="pmc:entrez-protein" xlink:href="Q93AU3">Q93AU3</ext-link>). The target
(IMP-7) and the template sequences were aligned using the Clustal
W method in Prime.<named-content content-type="bibref-group">
<xref rid="ref65" ref-type="bibr"/>,<xref rid="ref66" ref-type="bibr"/>
</named-content> The homology model of IMP-7 was
finally built using Prime in the Schrodinger Suite 2022&#8211;4.<named-content content-type="bibref-group">
<xref rid="ref67" ref-type="bibr"/>&#8722;<xref rid="ref68" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref69" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref70" ref-type="bibr"/>
</named-content> The modeled 3D structure of IMP-7 was further minimized for 5000
iterations using Amber22,<xref rid="ref71" ref-type="bibr"/> before being
used as a receptor in docking simulations.</p><p>Small molecules <bold>6c</bold>, <bold>6d</bold>, and <bold>6e</bold> were sketched in
2D (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">Supporting Figures S3 and S4</ext-link>) with
the Picto software version 4.5.4.1 (OpenEye Cadence Molecular Sciences,
Santa Fe, NM)<xref rid="ref72" ref-type="bibr"/> and converted into a 3D
structure with OMEGA version 4.2.0.1 (OpenEye Cadence Molecular Sciences,
Santa Fe, NM).<named-content content-type="bibref-group">
<xref rid="ref73" ref-type="bibr"/>,<xref rid="ref74" ref-type="bibr"/>
</named-content> The protonation state of the
molecule was predicted at pH 7.4 using the p<italic toggle="yes">K</italic>
<sub>a</sub> prediction software MOKA,<named-content content-type="bibref-group">
<xref rid="ref75" ref-type="bibr"/>&#8722;<xref rid="ref76" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref77" ref-type="bibr"/>
</named-content> whereas the sulfhydryl
group was considered as deprotonated to mimic Zn&#173;(II) coordination.
Ligand energy minimization was performed with SZYBKI version 2.5.0.1
(OpenEye Cadence Molecular Sciences, Santa Fe, NM)<xref rid="ref78" ref-type="bibr"/> using the MMFF94S force field.<xref rid="ref79" ref-type="bibr"/> SZMAP version 1.6.4.1. (OpenEye, Cadence Molecular Sciences, Santa
Fe, NM)<xref rid="ref80" ref-type="bibr"/> was used to assess the thermodynamic
contribution of crystallographic water molecules, where available.
Molecular docking was carried out with the GOLD program (The Cambridge
Crystallographic Data Centre) version 2023.1.0 using the GOLDSCORE
fitness function for docking and scoring purposes.<named-content content-type="bibref-group">
<xref rid="ref79" ref-type="bibr"/>,<xref rid="ref81" ref-type="bibr"/>
</named-content> The spherical binding site was centered within the two zinc atoms,
and it had a radius of 14 &#197;. Water molecules identified by SZMAP
were retained in the receptor structure during docking simulations.
Ten docking runs for each ligand were stored and submitted to visual
inspection.</p></sec><sec id="sec4.3.2"><label>4.3.2</label><title>Molecular Dynamics</title><p>For MD purposes,
the Zn&#173;(II) coordination systems were prepared using a QM/MM strategy
according to the MCPB.py approach.<named-content content-type="bibref-group">
<xref rid="ref82" ref-type="bibr"/>,<xref rid="ref83" ref-type="bibr"/>
</named-content> Accordingly,
the Zn1 atom was bound to the three coordinating histidine residues,
whereas the Zn2 atom was bound to histidine, cysteine, and aspartate.
The ligand was modeled through a nonbonding approach. Ligand partial
charges are assigned at the ami1-bcc level using antechamber.<named-content content-type="bibref-group">
<xref rid="ref84" ref-type="bibr"/>,<xref rid="ref85" ref-type="bibr"/>
</named-content> The ff19SB force field<xref rid="ref86" ref-type="bibr"/> was used to
parametrize the protein, and the general amber force field (GAFF)<xref rid="ref87" ref-type="bibr"/> was used to parametrize the ligands. TIP3P-type
water molecules and counterions were added to a rectangular box for
solvating each complex with a buffer of 10 &#197; from the molecular
system. MD simulations were run with Amber22.<xref rid="ref71" ref-type="bibr"/> Briefly, for each system, the solvent was first energy minimized
for 1500 steps using the steepest descent algorithm (SD), followed
by 5000 steps with the conjugate gradient algorithm (CG) while the
solute was frozen. The solvated solute was then energy minimized for
1500 steps with the SD and 5000 subsequent steps with the CG before
being heated to 300 K for 1 ns at a constant volume using the Langevin
thermostat. The system&#8217;s density was equilibrated for 1 ns
by the Berendsen barostat at constant pressure, and then a preliminary
equilibration of 50 ns was run before the final production of MD trajectories
lasting 500 ns. The time step was 2 fs in all MD simulations. MD trajectories
were analyzed by the CPPTRAJ software,<xref rid="ref88" ref-type="bibr"/> and frame clustering was carried out with an agglomerative hierarchical
algorithm.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00750_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00750_si_002.csv" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile3" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00750_si_003.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ACK-d14e3910-autogenerated"><p>S.P. acknowledges
MUR (Ministero dell&#8217;Universit&#224;
e della Ricerca), PON R&amp;I 2014-2020-Asse IV &#8220;Istruzione
e Ricerca per il recupero-REACT-EU&#8221;, Azione IV.6 &#8220;Contratti
di Ricerca su tematiche Green&#8221;. This research was supported
by EU funding within the MUR PNRR Extended Partnership initiative
on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT).
This study was also supported by the Next Generation EU project within
the MUR PNRR &#8220;National Center for Gene Therapy and Drugs based
on RNA Technology&#8221; (Project No. CN00000041 CN3 RNA). This manuscript
is also based upon work from COST Action EURESTOP, CA21145, supported
by COST (European Cooperation in Science and Technology). The authors
thank Domp&#233; Farmaceutici SpA for partially funding the PhD
scholarship of S.B. J.D.D. was supported in part by the Italian Ministry
of University and Research and the European Union (&#8220;Unione
Europea-Next Generation EU, Missione 4 Componente 2 Inv. 1.5 CUP_B63C22001400007)
in the frame of the PNRR PE-13 (&#8220;Piano Nazionale di Ripresa
e Resilienza, Partenariato Esteso 13, Malattie infettive emergenti&#8221;)
INF-ACT project (One Health Basic and Translational Research Actions
addressing Unmet Needs on Emerging Infectious Diseases). S.C. received
a PhD fellowship from the Italian MUR (Ministero dell&#8217;Universit&#224;
e della Ricerca), in the frame of the National PhD School &#8220;Innovazione
nella diagnosi, prevenzione e terapia delle infezioni a rischio epidemico-pandemico&#8221;.</p></ack><notes id="notes-1" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00750?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00750</ext-link>.<list list-type="simple" id="silist"><list-item><p>Copies of <sup>1</sup> H and <sup>13</sup>C NMR spectra;
HRMS and LC-MS spectra; HPLC chromatograms; additional computational
figures and 2D sketch presentations; and detailed results for the
DFT and TDDFT computational study on the stereochemical characterization
of compound <bold>14b</bold> (Tables S1&#8211;S5) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item><list-item><p>XYZ
structures of optimized conformers (provided as
compressed folder) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00750/suppl_file/jm5c00750_si_003.zip" ext-link-type="uri">ZIP</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-2" notes-type="author-contributions"><label>&#9675;</label><p>A.I.A. and S.P. contributed equally to this
work.</p></notes><notes id="NOTES-d14e3946-autogenerated" notes-type="conflict-of-interest"><p>The authors
declare no
competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><article-title>A hydroxide lock for
metallo-beta-lactamases</article-title><source>Nat. Chem.</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>6</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41557-021-00871-3</pub-id><pub-id pub-id-type="pmid">34987173</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Miller</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>Arias</surname><given-names>C. A.</given-names></name><article-title>ESKAPE pathogens:
antimicrobial resistance, epidemiology,
clinical impact and therapeutics</article-title><source>Nat. Rev.
Microbiol.</source><year>2024</year><volume>22</volume><issue>10</issue><fpage>598</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1038/s41579-024-01054-w</pub-id><pub-id pub-id-type="pmid">38831030</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Denissen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reyneke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Waso-Reyneke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Havenga</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.</given-names></name><article-title>Prevalence
of ESKAPE pathogens in
the environment: Antibiotic resistance status, community-acquired
infection and risk to human health</article-title><source>Int. J.
Hyg. Environ. Health</source><year>2022</year><volume>244</volume><elocation-id>114006</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijheh.2022.114006</pub-id><pub-id pub-id-type="pmid">35841823</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Daruka</surname><given-names>L.</given-names></name><name name-style="western"><surname>Czikkely</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Szili</surname><given-names>P.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Balogh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grezal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maharramov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Sipos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Juhasz</surname><given-names>S.</given-names></name><etal/><article-title>ESKAPE
pathogens rapidly develop resistance against
antibiotics in development in vitro</article-title><source>Nat. Microbiol.</source><year>2025</year><volume>10</volume><issue>2</issue><fpage>313</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/s41564-024-01891-8</pub-id><pub-id pub-id-type="pmid">39805953</pub-id><pub-id pub-id-type="pmcid">PMC11790497</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Mulani</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Kamble</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Kumkar</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Tawre</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Pardesi</surname><given-names>K. R.</given-names></name><article-title>Emerging
Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial
Resistance: A Review</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>539</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.00539</pub-id><pub-id pub-id-type="pmid">30988669</pub-id><pub-id pub-id-type="pmcid">PMC6452778</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Kalpana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lakshmi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H. Y.</given-names></name><article-title>Antibiotic Resistance Diagnosis in
ESKAPE Pathogens-A
Review on Proteomic Perspective</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><issue>6</issue><elocation-id>1014</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics13061014</pub-id><pub-id pub-id-type="pmid">36980322</pub-id><pub-id pub-id-type="pmcid">PMC10047325</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Mojica</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Vila</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>R. A.</given-names></name><article-title>The urgent need
for metallo-beta-lactamase inhibitors: an unattended global threat</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>e28</fpage><lpage>e34</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30868-9</pub-id><pub-id pub-id-type="pmid">34246322</pub-id><pub-id pub-id-type="pmcid">PMC8266270</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Ikuta</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Sharara</surname><given-names>F.</given-names></name><collab>Antimicrobial
Resistance, C.</collab><article-title>Global burden
of bacterial antimicrobial
resistance in 2019: a systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><issue>10325</issue><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Seguin-Devaux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mestrovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arts</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Sen Karaman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nativi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reichmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sahariah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Smani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rijo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>M.</given-names></name><etal/><article-title>Solving the antibacterial
resistance in Europe: The multipronged approach of the COST Action
CA21145 EURESTOP</article-title><source>Drug Resistance Updates</source><year>2024</year><volume>74</volume><elocation-id>101069</elocation-id><pub-id pub-id-type="doi">10.1016/j.drup.2024.101069</pub-id><pub-id pub-id-type="pmid">38458099</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Rawson</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>L. S. P.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Skolimowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>G.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>A.</given-names></name><article-title>Bacterial and Fungal
Coinfection in Individuals With
Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><issue>9</issue><fpage>2459</fpage><lpage>2468</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa530</pub-id><pub-id pub-id-type="pmid">32358954</pub-id><pub-id pub-id-type="pmcid">PMC7197596</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Liu</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L. X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Doi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><etal/><article-title>Emergence
of plasmid-mediated colistin resistance mechanism
MCR-1 in animals and human beings in China: a microbiological and
molecular biological study</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><issue>2</issue><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00424-7</pub-id><pub-id pub-id-type="pmid">26603172</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/><article-title>Emergence of plasmid-mediated
high-level tigecycline resistance genes
in animals and humans</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><issue>9</issue><fpage>1450</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0445-2</pub-id><pub-id pub-id-type="pmid">31133751</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><etal/><article-title>Clinical course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id><pub-id pub-id-type="pmcid">PMC7270627</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Kumarasamy</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Toleman</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Bagaria</surname><given-names>J.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Balakrishnan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>U.</given-names></name><name name-style="western"><surname>Doumith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giske</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Irfan</surname><given-names>S.</given-names></name><etal/><article-title>Emergence of a new antibiotic resistance mechanism
in India, Pakistan, and the UK: a molecular, biological, and epidemiological
study</article-title><source>Lancet Infect. Dis.</source><year>2010</year><volume>10</volume><issue>9</issue><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(10)70143-2</pub-id><pub-id pub-id-type="pmid">20705517</pub-id><pub-id pub-id-type="pmcid">PMC2933358</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Tooke</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Hinchliffe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bragginton</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Colenso</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Hirvonen</surname><given-names>V. H. A.</given-names></name><name name-style="western"><surname>Takebayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J.</given-names></name><article-title>beta-Lactamases and beta-Lactamase
Inhibitors in the 21st Century</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><issue>18</issue><fpage>3472</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.04.002</pub-id><pub-id pub-id-type="pmid">30959050</pub-id><pub-id pub-id-type="pmcid">PMC6723624</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Bush</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>P. A.</given-names></name><article-title>Epidemiology of beta-Lactamase-Producing Pathogens</article-title><source>Clin. Microbiol. Rev.</source><year>2020</year><volume>33</volume><issue>2</issue><elocation-id>e00047-19</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00047-19</pub-id><pub-id pub-id-type="pmid">32102899</pub-id><pub-id pub-id-type="pmcid">PMC7048014</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Bush</surname><given-names>K.</given-names></name><article-title>The ABCD&#8217;s
of beta-lactamase nomenclature</article-title><source>J. Infect. Chemother.</source><year>2013</year><volume>19</volume><issue>4</issue><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1007/s10156-013-0640-7</pub-id><pub-id pub-id-type="pmid">23828655</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>McNally</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Z.</given-names></name><article-title>NDM Metallo-beta-Lactamases
and Their Bacterial Producers in Health
Care Settings</article-title><source>Clin. Microbiol. Rev.</source><year>2019</year><volume>32</volume><issue>2</issue><elocation-id>e00115-18</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00115-18</pub-id><pub-id pub-id-type="pmid">30700432</pub-id><pub-id pub-id-type="pmcid">PMC6431124</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Ehmann</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Jahic</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>G.</given-names></name><name name-style="western"><surname>Walkup</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>S. L.</given-names></name><article-title>Avibactam is a covalent,
reversible, non-beta-lactam beta-lactamase inhibitor</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2012</year><volume>109</volume><issue>29</issue><fpage>11663</fpage><lpage>11668</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205073109</pub-id><pub-id pub-id-type="pmid">22753474</pub-id><pub-id pub-id-type="pmcid">PMC3406822</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Lomovskaya</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rubio-Aparicio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsivkovski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M. N.</given-names></name><article-title>Vaborbactam:
Spectrum of Beta-Lactamase
Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><issue>11</issue><elocation-id>e01443-17</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01443-17</pub-id><pub-id pub-id-type="pmid">28848018</pub-id><pub-id pub-id-type="pmcid">PMC5655098</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Bahr</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Vila</surname><given-names>A. J.</given-names></name><article-title>Metallo-beta-lactamases in the Age
of Multidrug Resistance: From Structure and Mechanism to Evolution,
Dissemination, and Inhibitor Design</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><issue>13</issue><fpage>7957</fpage><lpage>8094</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.1c00138</pub-id><pub-id pub-id-type="pmid">34129337</pub-id><pub-id pub-id-type="pmcid">PMC9062786</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Tyers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>G. D.</given-names></name><article-title>Drug combinations: a strategy to extend the life of
antibiotics in the 21st century</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><issue>3</issue><fpage>141</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0141-x</pub-id><pub-id pub-id-type="pmid">30683887</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Davies</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Everett</surname><given-names>M.</given-names></name><article-title>Designing Inhibitors of beta-Lactamase Enzymes to Overcome
Carbapenem Resistance in Gram-Negative Bacteria</article-title><source>Acc. Chem. Res.</source><year>2021</year><volume>54</volume><issue>9</issue><fpage>2055</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.0c00863</pub-id><pub-id pub-id-type="pmid">33788541</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Yan</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><article-title>Discovery of mercaptopropanamide-substituted
aryl tetrazoles as new broad-spectrum metallo-beta-lactamase inhibitors</article-title><source>RSC Adv.</source><year>2020</year><volume>10</volume><issue>52</issue><fpage>31377</fpage><lpage>31384</lpage><pub-id pub-id-type="doi">10.1039/D0RA06405J</pub-id><pub-id pub-id-type="pmid">35520685</pub-id><pub-id pub-id-type="pmcid">PMC9056430</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Lima</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>E. J.</given-names></name><article-title>beta-lactam antibiotics:
An overview from a medicinal chemistry perspective</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>208</volume><elocation-id>112829</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112829</pub-id><pub-id pub-id-type="pmid">33002736</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Ju</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fast</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Crowder</surname><given-names>M. W.</given-names></name><article-title>The Continuing
Challenge of Metallo-beta-Lactamase Inhibition: Mechanism Matters</article-title><source>Trends Pharmacol. Sci.</source><year>2018</year><volume>39</volume><issue>7</issue><fpage>635</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.03.007</pub-id><pub-id pub-id-type="pmid">29680579</pub-id><pub-id pub-id-type="pmcid">PMC6005755</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Parkova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krajnc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brem</surname><given-names>J.</given-names></name><name name-style="western"><surname>Calvopina</surname><given-names>K.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Trapencieris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>C. J.</given-names></name><article-title>Broad Spectrum beta-Lactamase Inhibition
by a Thioether
Substituted Bicyclic Boronate</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><issue>6</issue><fpage>1398</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00330</pub-id><pub-id pub-id-type="pmid">31841636</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Palacios</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Mojica</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taracila</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Bethel</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Alzari</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Otero</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Klinke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Llarrull</surname><given-names>L. I.</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>R. A.</given-names></name><etal/><article-title>The Reaction Mechanism of Metallo-beta-Lactamases
Is Tuned by the Conformation of an Active-Site Mobile Loop</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><issue>1</issue><elocation-id>e01754-18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01754-18</pub-id><pub-id pub-id-type="pmcid">PMC6325180</pub-id><pub-id pub-id-type="pmid">30348667</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Jobin</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Overall</surname><given-names>C. M.</given-names></name><article-title>New intracellular activities of matrix
metalloproteinases shine in the moonlight</article-title><source>Biochim.
Biophys. Acta, Mol. Cell Res.</source><year>2017</year><volume>1864</volume><issue>11 Pt A</issue><fpage>2043</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2017.05.013</pub-id><pub-id pub-id-type="pmid">28526562</pub-id></element-citation></ref><ref id="ref30"><mixed-citation publication-type="weblink" id="cit30"><year>2024</year><uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT03840148">https://clinicaltrials.gov/ct2/show/NCT03840148</uri>. (accessed
December 6th 2024).</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="weblink" id="cit31"><year>2024</year><uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04380207">https://clinicaltrials.gov/ct2/show/NCT04380207</uri>. (accessed
December 6th 2024).</mixed-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Rydzik</surname><given-names>A.
M.</given-names></name><name name-style="western"><surname>Brem</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Berkel</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Makena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Claridge</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>C. J.</given-names></name><article-title>Monitoring conformational changes
in the NDM-1 metallo-beta-lactamase by 19F NMR spectroscopy</article-title><source>Angew. Chem., Int. Ed.</source><year>2014</year><volume>53</volume><issue>12</issue><fpage>3129</fpage><lpage>3133</lpage><pub-id pub-id-type="doi">10.1002/anie.201310866</pub-id><pub-id pub-id-type="pmcid">PMC4499255</pub-id><pub-id pub-id-type="pmid">24615874</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>King</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Worrall</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Gruninger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Strynadka</surname><given-names>N. C. J.</given-names></name><article-title>New
Delhi Metallo-&#946;-Lactamase: Structural Insights into &#946;-Lactam
Recognition and Inhibition</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><issue>28</issue><fpage>11362</fpage><lpage>11365</lpage><pub-id pub-id-type="doi">10.1021/ja303579d</pub-id><pub-id pub-id-type="pmid">22713171</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><article-title>Structure-guided optimization of
D-captopril for discovery of potent NDM-1 inhibitors</article-title><source>Bioorg. Med. Chem.</source><year>2021</year><volume>29</volume><elocation-id>115902</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115902</pub-id><pub-id pub-id-type="pmid">33302045</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shui</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Z.</given-names></name><article-title>A structural view of the antibiotic degradation enzyme NDM-1 from
a superbug</article-title><source>Protein Cell</source><year>2011</year><volume>2</volume><issue>5</issue><fpage>384</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1007/s13238-011-1055-9</pub-id><pub-id pub-id-type="pmid">21637961</pub-id><pub-id pub-id-type="pmcid">PMC4875342</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Klingler</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Wichelhaus</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cuesta-Bernal</surname><given-names>J.</given-names></name><name name-style="western"><surname>El-Delik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>H. F.</given-names></name><name name-style="western"><surname>Sjuts</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gottig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koenigs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pos</surname><given-names>K. M.</given-names></name><etal/><article-title>Approved Drugs Containing
Thiols as Inhibitors of Metallo-beta-lactamases: Strategy To Combat
Multidrug-Resistant Bacteria</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><issue>8</issue><fpage>3626</fpage><lpage>3630</lpage><pub-id pub-id-type="doi">10.1021/jm501844d</pub-id><pub-id pub-id-type="pmid">25815530</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Buttner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Klingler</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Wittmann</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Kohnhauser</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weizel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bruggerhoff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D.</given-names></name><etal/><article-title>Challenges
in the Development of a Thiol-Based Broad-Spectrum
Inhibitor for Metallo-beta-Lactamases</article-title><source>ACS Infect.
Dis.</source><year>2018</year><volume>4</volume><issue>3</issue><fpage>360</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00129</pub-id><pub-id pub-id-type="pmid">29172434</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Alfano</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Zampella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Novellino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brindisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>H.</given-names></name><article-title>Harnessing
interrupted Fischer in continuous flow: sustainable synthesis of (spiro)&#173;indolenine
and (spiro)&#173;indoline privileged scaffolds</article-title><source>React.
Chem. Eng.</source><year>2020</year><volume>5</volume><issue>11</issue><fpage>2091</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1039/D0RE00329H</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Alfano</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Buommino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Irace</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zampella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brindisi</surname><given-names>M.</given-names></name><article-title>Coupling Interrupted Fischer and
Multicomponent Joullie-Ugi to Chase Chemical Diversity: from Batch
to Sustainable Flow Synthesis of Peptidomimetics</article-title><source>ChemMedChem</source><year>2021</year><volume>16</volume><issue>24</issue><fpage>3795</fpage><lpage>3809</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202100474</pub-id><pub-id pub-id-type="pmid">34585536</pub-id><pub-id pub-id-type="pmcid">PMC9297956</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Jones</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Hynd</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><article-title>On the selective deprotection
of trityl ethers</article-title><source>J. Org. Chem.</source><year>2000</year><volume>65</volume><issue>1</issue><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1021/jo9913255</pub-id><pub-id pub-id-type="pmid">10813927</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Yusof</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D. T. C.</given-names></name><name name-style="western"><surname>Arjomandi</surname><given-names>O. K.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>G.</given-names></name><name name-style="western"><surname>McGeary</surname><given-names>R. P.</given-names></name><article-title>Captopril
analogues as metallo-&#946;-lactamase inhibitors</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2016</year><volume>26</volume><issue>6</issue><fpage>1589</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2016.02.007</pub-id><pub-id pub-id-type="pmid">26883147</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Kaya</surname><given-names>C.</given-names></name><name name-style="western"><surname>Konstantinovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kany</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Andreas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Brunst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weizel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rotter</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yahiaoui</surname><given-names>S.</given-names></name><etal/><article-title>-Aryl Mercaptopropionamides as Broad-Spectrum
Inhibitors of Metallo-&#946;-Lactamases</article-title><source>J.
Med. Chem.</source><year>2022</year><volume>65</volume><issue>5</issue><fpage>3913</fpage><lpage>3922</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c01755</pub-id><pub-id pub-id-type="pmid">35188771</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Rukavishnikov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Corry</surname><given-names>S.</given-names></name><article-title>Fluorogenic
cephalosporin
substrates for &#946;-lactamase TEM-1</article-title><source>Anal.
Biochem.</source><year>2011</year><volume>419</volume><issue>1</issue><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2011.07.020</pub-id><pub-id pub-id-type="pmid">21867672</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44a"><label>a</label><name name-style="western"><surname>Pescitelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bruhn</surname><given-names>T.</given-names></name><article-title>Good Computational
Practice in the Assignment of Absolute Configurations by TDDFT Calculations
of ECD Spectra</article-title><source>Chirality</source><year>2016</year><volume>28</volume><issue>6</issue><fpage>466</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1002/chir.22600</pub-id><pub-id pub-id-type="pmid">27098594</pub-id></element-citation><element-citation publication-type="journal" id="cit44b"><label>b</label><name name-style="western"><surname>Masi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poppi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Previtali</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Wynne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Varignani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Veronesi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Albanesi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tedesco</surname><given-names>D.</given-names></name><etal/><article-title>Investigating synthetic lethality and PARP inhibitor resistance in
pancreatic cancer through enantiomer differential activity</article-title><source>Cell Death Discovery</source><year>2025</year><volume>11</volume><issue>1</issue><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-025-02382-3</pub-id><pub-id pub-id-type="pmid">40091075</pub-id><pub-id pub-id-type="pmcid">PMC11911456</pub-id></element-citation></ref><ref id="ref45"><mixed-citation publication-type="weblink" id="cit45"><article-title>DKit: Open-Source Cheminformatics</article-title>, R, version, <year>2025</year>. <uri xlink:href="https://www.rdkit.org">https://www.rdkit.org</uri>. March 02, 2025.</mixed-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Riniker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Landrum</surname><given-names>G. A.</given-names></name><article-title>Better Informed Distance Geometry: Using What We Know
To Improve Conformation Generation</article-title><source>J. Chem.
Inf. Model.</source><year>2015</year><volume>55</volume><issue>12</issue><fpage>2562</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.5b00654</pub-id><pub-id pub-id-type="pmid">26575315</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Halgren</surname><given-names>T. A.</given-names></name><article-title>MMFF VI.
MMFF94s option for energy minimization studies</article-title><source>J. Comput. Chem.</source><year>1999</year><volume>20</volume><issue>7</issue><fpage>720</fpage><lpage>729</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-987X(199905)20:7&amp;#x0003c;720::AID-JCC7&amp;#x0003e;3.0.CO;2-X</pub-id><pub-id pub-id-type="pmid">34376030</pub-id></element-citation><note><p>From NLM PubMed-not-MEDLINE.</p></note></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Grimme</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goerigk</surname><given-names>L.</given-names></name><article-title>Effect of the damping function in
dispersion corrected density functional theory</article-title><source>J. Comput. Chem.</source><year>2011</year><volume>32</volume><issue>7</issue><fpage>1456</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1002/jcc.21759</pub-id><pub-id pub-id-type="pmid">21370243</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Weigend</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ahlrichs</surname><given-names>R.</given-names></name><article-title>Balanced basis sets
of split valence, triple zeta valence
and quadruple zeta valence quality for H to Rn: Design and assessment
of accuracy</article-title><source>Phys. Chem. Chem. Phys.</source><year>2005</year><volume>7</volume><issue>18</issue><fpage>3297</fpage><lpage>3305</lpage><pub-id pub-id-type="doi">10.1039/b508541a</pub-id><pub-id pub-id-type="pmid">16240044</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Weigend</surname><given-names>F.</given-names></name><article-title>Accurate Coulomb-fitting
basis sets for H to Rn</article-title><source>Phys. Chem. Chem. Phys.</source><year>2006</year><volume>8</volume><issue>9</issue><fpage>1057</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1039/b515623h</pub-id><pub-id pub-id-type="pmid">16633586</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Dunlap</surname><given-names>B.
I.</given-names></name><article-title>Fitting
the Coulomb Potential Variationally in X-Alpha Molecular Calculations</article-title><source>J. Chem. Phys.</source><year>1983</year><volume>78</volume><issue>6</issue><fpage>3140</fpage><lpage>3142</lpage><pub-id pub-id-type="doi">10.1063/1.445228</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Dunlap</surname><given-names>B. I.</given-names></name><article-title>Robust
and variational fitting: Removing the four-center integrals from center
stage in quantum chemistry</article-title><source>J. Mol. Struct.:THEOCHEM</source><year>2000</year><volume>529</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0166-1280(00)00528-5</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Tomasi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mennucci</surname><given-names>B.</given-names></name><name name-style="western"><surname>Canc&#232;s</surname><given-names>E.</given-names></name><article-title>The IEF version
of the PCM solvation
method:: an overview of a new method addressed to study molecular
solutes at the QM ab initio level</article-title><source>J. Mol. Struct.:THEOCHEM</source><year>1999</year><volume>464</volume><issue>1&#8211;3</issue><fpage>211</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/S0166-1280(98)00553-3</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Guido</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Bremond</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cortona</surname><given-names>P.</given-names></name><article-title>Communication: one
third: a new recipe for the PBE0 paradigm</article-title><source>J.
Chem. Phys.</source><year>2013</year><volume>138</volume><issue>2</issue><elocation-id>021104</elocation-id><pub-id pub-id-type="doi">10.1063/1.4775591</pub-id><pub-id pub-id-type="pmid">23320660</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Rappoport</surname><given-names>D.</given-names></name><name name-style="western"><surname>Furche</surname><given-names>F.</given-names></name><article-title>Property-optimized gaussian basis sets for molecular
response calculations</article-title><source>J. Chem. Phys.</source><year>2010</year><volume>133</volume><issue>13</issue><elocation-id>134105</elocation-id><pub-id pub-id-type="doi">10.1063/1.3484283</pub-id><pub-id pub-id-type="pmid">20942521</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Pritchard</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Altarawy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Didier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Windus</surname><given-names>T. L.</given-names></name><article-title>New Basis
Set Exchange: An Open, Up-to-Date Resource for the Molecular Sciences
Community</article-title><source>J. Chem. Inf. Model.</source><year>2019</year><volume>59</volume><issue>11</issue><fpage>4814</fpage><lpage>4820</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b00725</pub-id><pub-id pub-id-type="pmid">31600445</pub-id></element-citation></ref><ref id="ref57"><mixed-citation publication-type="book" id="cit57"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Frisch</surname>, <given-names>M. J. T.</given-names></string-name>; <string-name name-style="western"><surname>G</surname>, <given-names>W.</given-names></string-name>; <string-name name-style="western"><surname>Schlegel</surname>, <given-names>H. B.</given-names></string-name>; <string-name name-style="western"><surname>Scuseria</surname>, <given-names>G. E.</given-names></string-name>; <string-name name-style="western"><surname>Robb</surname>, <given-names>M. A.</given-names></string-name>; <string-name name-style="western"><surname>Cheeseman</surname>, <given-names>J. R.</given-names></string-name>; <string-name name-style="western"><surname>Scalmani</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western"><surname>Barone</surname>, <given-names>V.</given-names></string-name>; <string-name name-style="western"><surname>Petersson</surname>, <given-names>G. A.</given-names></string-name>; <string-name name-style="western"><surname>Nakatsuji</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Li</surname>, <given-names>X.</given-names></string-name>; <string-name name-style="western"><surname>Caricato</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Marenich</surname>, <given-names>A. V.</given-names></string-name>; <string-name name-style="western"><surname>Bloino</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Janesko</surname>, <given-names>B. G.</given-names></string-name>; <string-name name-style="western"><surname>Gomperts</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Mennucci</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western"><surname>Hratchian</surname>, <given-names>H. P.</given-names></string-name>; <string-name name-style="western"><surname>Ortiz</surname>, <given-names>J. V.</given-names></string-name>; <string-name name-style="western"><surname>Izmaylov</surname>, <given-names>A. F.</given-names></string-name>; <string-name name-style="western"><surname>Sonnenberg</surname>, <given-names>J. L.</given-names></string-name>; <string-name name-style="western"><surname>Williams-Young</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western"><surname>Ding</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Lipparini</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Egidi</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Goings</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Peng</surname>, <given-names>B.</given-names></string-name>; <string-name name-style="western"><surname>Petrone</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Henderson</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Ranasinghe</surname>, <given-names>D.</given-names></string-name>; <string-name name-style="western"><surname>Zakrzewski</surname>, <given-names>V. G.</given-names></string-name>; <string-name name-style="western"><surname>Gao</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Rega</surname>, <given-names>N.</given-names></string-name>; <string-name name-style="western"><surname>Zheng</surname>, <given-names>G.</given-names></string-name>; <string-name name-style="western"><surname>Liang</surname>, <given-names>W.</given-names></string-name>; <string-name name-style="western"><surname>Hada</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Ehara</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Toyota</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Fukuda</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Hasegawa</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Ishida</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Nakajima</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Honda</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western"><surname>Kitao</surname>, <given-names>O.</given-names></string-name>; <string-name name-style="western"><surname>Nakai</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Vreven</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Throssell</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Montgomery</surname>, <given-names>J. A.</given-names>, <suffix>Jr.</suffix></string-name>; <string-name name-style="western"><surname>Peralta</surname>, <given-names>J. E.</given-names></string-name>; <string-name name-style="western"><surname>Ogliaro</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Bearpark</surname>, <given-names>M. J.</given-names></string-name>; <string-name name-style="western"><surname>Heyd</surname>, <given-names>J. J.</given-names></string-name>; <string-name name-style="western"><surname>Brothers</surname>, <given-names>E. N.</given-names></string-name>; <string-name name-style="western"><surname>Kudin</surname>, <given-names>K. N.</given-names></string-name>; <string-name name-style="western"><surname>Staroverov</surname>, <given-names>V. N.</given-names></string-name>; <string-name name-style="western"><surname>Keith</surname>, <given-names>T. A.</given-names></string-name>; <string-name name-style="western"><surname>Kobayashi</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Normand</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Raghavachari</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Rendell</surname>, <given-names>A. P.</given-names></string-name>; <string-name name-style="western"><surname>Burant</surname>, <given-names>J. C.</given-names></string-name>; <string-name name-style="western"><surname>Iyengar</surname>, <given-names>S. S.</given-names></string-name>; <string-name name-style="western"><surname>Tomasi</surname>, <given-names>J.</given-names></string-name>; <string-name name-style="western"><surname>Cossi</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Millam</surname>, <given-names>J. M.</given-names></string-name>; <string-name name-style="western"><surname>Klene</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Adamo</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western"><surname>Cammi</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Ochterski</surname>, <given-names>J. W.</given-names></string-name>; <string-name name-style="western"><surname>Martin</surname>, <given-names>R. L.</given-names></string-name>; <string-name name-style="western"><surname>Morokuma</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Farkas</surname>, <given-names>O.</given-names></string-name>; <string-name name-style="western"><surname>Foresman</surname>, <given-names>J. B.</given-names></string-name>; <string-name name-style="western"><surname>Fox</surname>, <given-names>D. J.</given-names></string-name></person-group><source>Gaussian 16</source>, Revision B.01; <publisher-name>Gaussian, Inc.</publisher-name>: <publisher-loc>Wallingford, CT</publisher-loc>, <year>2016</year>.</mixed-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Legru</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verdirosa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vo-Hoang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tassone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vascon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Sannio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corsica</surname><given-names>G.</given-names></name><name name-style="western"><surname>Benvenuti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feller</surname><given-names>G.</given-names></name><etal/><article-title>Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum
Metallo-beta-lactamase Inhibitors Showing Potent Synergistic Activity
on VIM- and NDM-1-Producing Clinical Isolates</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>24</issue><fpage>16392</fpage><lpage>16419</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01257</pub-id><pub-id pub-id-type="pmid">36450011</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Mandal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Scapin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Root</surname><given-names>Y.</given-names></name><name name-style="western"><surname>de Jesus</surname><given-names>R. K.</given-names></name><etal/><article-title>Rapid Evolution of a
Fragment-like Molecule
to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical
Candidates</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>24</issue><fpage>16234</fpage><lpage>16251</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00766</pub-id><pub-id pub-id-type="pmid">36475645</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Wang</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z. J.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><etal/><article-title>Structure-Based
Development of (1-(3&#8242;-Mercaptopropanamido)&#173;methyl)&#173;boronic Acid
Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-beta-lactamases</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><issue>15</issue><fpage>7160</fpage><lpage>7184</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00735</pub-id><pub-id pub-id-type="pmid">31269398</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Yan</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/><article-title>Metal
binding pharmacophore click-derived discovery
of new broad-spectrum metallo-beta-lactamase inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>257</volume><elocation-id>115473</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115473</pub-id><pub-id pub-id-type="pmid">37209449</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Berman</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Battistuz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Bluhm</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iype</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marvin</surname><given-names>J.</given-names></name><etal/><article-title>The Protein Data Bank</article-title><source>Acta Crystallogr.,
Sect. D: Biol. Crystallogr.</source><year>2002</year><volume>58</volume><fpage>899</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1107/S0907444902003451</pub-id><pub-id pub-id-type="pmid">12037327</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Ho</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Palasubramaniam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Navaratnam</surname><given-names>P.</given-names></name><article-title>Carbapenem-resistant
Pseudomonas aeruginosa in malaysia producing IMP-7 beta-lactamase</article-title><source>Antimicrob. Agents Chemother.</source><year>2002</year><volume>46</volume><issue>10</issue><fpage>3286</fpage><lpage>3287</lpage><pub-id pub-id-type="doi">10.1128/AAC.46.10.3286-3287.2002</pub-id><pub-id pub-id-type="pmid">12234862</pub-id><pub-id pub-id-type="pmcid">PMC128803</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Bateman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Orchard</surname><given-names>S.</given-names></name><etal/><article-title>UniProt: the Universal
Protein Knowledgebase in 2023</article-title><source>Nucleic Acids
Res.</source><year>2023</year><volume>51</volume><issue>D1</issue><fpage>D523</fpage><lpage>D531</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1052</pub-id><pub-id pub-id-type="pmid">36408920</pub-id><pub-id pub-id-type="pmcid">PMC9825514</pub-id></element-citation></ref><ref id="ref65"><mixed-citation publication-type="other" id="cit65"><article-title>Clustalw U, To
C, Multiple DO. ClustalW and ClustalX. Options</article-title>, <year>2003</year>. Chapter 2.</mixed-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Thompson</surname><given-names>J.
D.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>D. G.</given-names></name><article-title>Multiple sequence alignment using
ClustalW and ClustalX</article-title><source>Curr. Protoc. Bioinf.</source><year>2003</year><fpage>2</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1002/0471250953.bi0203s00</pub-id><pub-id pub-id-type="pmid">18792934</pub-id></element-citation></ref><ref id="ref67"><mixed-citation publication-type="book" id="cit67"><source>Schr&#246;dinger Release 2022&#8211;4: Maestro</source>; <publisher-name>Schr&#246;dinger, LLC</publisher-name>: <publisher-loc>New York,
NY</publisher-loc>, <year>2022</year>.</mixed-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Jacobson</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Pincus</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Day</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Friesner</surname><given-names>R. A.</given-names></name><article-title>A hierarchical approach to all-atom
protein loop prediction</article-title><source>Proteins</source><year>2004</year><volume>55</volume><issue>2</issue><fpage>351</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1002/prot.10613</pub-id><pub-id pub-id-type="pmid">15048827</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Jacobson</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Friesner</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>B.</given-names></name><article-title>On the role of the
crystal environment in determining protein side-chain conformations</article-title><source>J. Mol. Biol.</source><year>2002</year><volume>320</volume><issue>3</issue><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(02)00470-9</pub-id><pub-id pub-id-type="pmid">12096912</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Ramachandran</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sasisekharan</surname><given-names>V.</given-names></name><article-title>Stereochemistry of Polypeptide-Chain
Configurations</article-title><source>Curr. Sci. India</source><year>1990</year><volume>59</volume><issue>17&#8211;18</issue><fpage>813</fpage><lpage>817</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-2836(63)80023-6</pub-id><pub-id pub-id-type="pmid">13990617</pub-id></element-citation></ref><ref id="ref71"><mixed-citation publication-type="book" id="cit71"><source>Amber 2022</source>; <publisher-name>University of California</publisher-name>, <publisher-loc>San Francisco</publisher-loc>.</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="book" id="cit72"><source>PICTO 4.5.4.1</source>; <publisher-name>OpenEye, Cadence
Molecular Sciences</publisher-name>: <publisher-loc>Santa Fe, NM</publisher-loc><uri xlink:href="http://www.eyesopen.com">http://www.eyesopen.com</uri>.</mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="book" id="cit73"><source>OMEGA 4.2.0.1</source>; <publisher-name>OpenEye, Cadence
Molecular Sciences</publisher-name>: <publisher-loc>Santa Fe, NM</publisher-loc><uri xlink:href="http://www.eyesopen.com">http://www.eyesopen.com</uri>.</mixed-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Hawkins</surname><given-names>P. C. D.</given-names></name><name name-style="western"><surname>Skillman</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Ellingson</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>M. T.</given-names></name><article-title>Conformer generation with OMEGA:
algorithm and validation
using high quality structures from the Protein Databank and Cambridge
Structural Database</article-title><source>J. Chem. Inf. Model.</source><year>2010</year><volume>50</volume><issue>4</issue><fpage>572</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1021/ci100031x</pub-id><pub-id pub-id-type="pmid">20235588</pub-id><pub-id pub-id-type="pmcid">PMC2859685</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Milletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vulpetti</surname><given-names>A.</given-names></name><article-title>Tautomer preference
in PDB complexes and its impact
on structure-based drug discovery</article-title><source>J. Chem.
Inf. Model.</source><year>2010</year><volume>50</volume><issue>6</issue><fpage>1062</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1021/ci900501c</pub-id><pub-id pub-id-type="pmid">20515065</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Milletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Storchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sforna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cruciani</surname><given-names>G.</given-names></name><article-title>Tautomer enumeration
and stability prediction for virtual screening on large chemical databases</article-title><source>J. Chem. Inf. Model.</source><year>2009</year><volume>49</volume><issue>1</issue><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1021/ci800340j</pub-id><pub-id pub-id-type="pmid">19123923</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Milletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Storchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sforna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cruciani</surname><given-names>G.</given-names></name><article-title>New and original pKa
prediction method using grid molecular interaction fields</article-title><source>J. Chem. Inf. Model.</source><year>2007</year><volume>47</volume><issue>6</issue><fpage>2172</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1021/ci700018y</pub-id><pub-id pub-id-type="pmid">17910431</pub-id></element-citation></ref><ref id="ref78"><mixed-citation publication-type="book" id="cit78"><source>SZYBKI 2.5.0.1</source>; <publisher-name>OpenEye, Cadence
Molecular Sciences</publisher-name>: <publisher-loc>Santa Fe, NM</publisher-loc><uri xlink:href="http://www.eyesopen.com">http://www.eyesopen.com</uri>.</mixed-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Verdonk</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Hartshorn</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R. D.</given-names></name><article-title>Improved
protein-ligand docking using GOLD</article-title><source>Proteins</source><year>2003</year><volume>52</volume><issue>4</issue><fpage>609</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1002/prot.10465</pub-id><pub-id pub-id-type="pmid">12910460</pub-id></element-citation></ref><ref id="ref80"><mixed-citation publication-type="book" id="cit80"><source>SZMAP 1.6.4.1</source>; <publisher-name>OpenEye, Cadence
Molecular Sciences</publisher-name>: <publisher-loc>Santa Fe, NM</publisher-loc>, <year>2013</year><uri xlink:href="http://www.eyesopen.com">http://www.eyesopen.com</uri>.</mixed-citation></ref><ref id="ref81"><element-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Jones</surname><given-names>G.</given-names></name><name name-style="western"><surname>Willett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Glen</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R.</given-names></name><article-title>Development
and validation of a genetic algorithm for flexible docking</article-title><source>J. Mol. Biol.</source><year>1997</year><volume>267</volume><issue>3</issue><fpage>727</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0897</pub-id><pub-id pub-id-type="pmid">9126849</pub-id></element-citation></ref><ref id="ref82"><element-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Merz</surname><given-names>K. M.</given-names><suffix>Jr.</suffix></name><article-title>MCPB.py: A Python Based Metal Center
Parameter Builder</article-title><source>J. Chem. Inf. Model</source><year>2016</year><volume>56</volume><issue>4</issue><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.5b00674</pub-id><pub-id pub-id-type="pmid">26913476</pub-id></element-citation></ref><ref id="ref83"><element-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Eshtiwi</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Rathbone</surname><given-names>D. L.</given-names></name><article-title>A modified bonded model approach for molecular dynamics
simulations of New Delhi Metallo-beta-lactamase</article-title><source>J. Mol. Graphics Modell.</source><year>2023</year><volume>121</volume><elocation-id>108431</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmgm.2023.108431</pub-id><pub-id pub-id-type="pmid">36827734</pub-id></element-citation></ref><ref id="ref84"><element-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Wang</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name><article-title>Antechamber: An
accessory software
package for molecular mechanical calculations</article-title><source>Abstr. Pap. Am. Chem. Soc.</source><year>2001</year><volume>222</volume><fpage>U403</fpage></element-citation></ref><ref id="ref85"><element-citation publication-type="journal" id="cit85"><name name-style="western"><surname>Wang</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name><article-title>Automatic atom type
and bond type perception in molecular mechanical calculations</article-title><source>J. Mol. Graphics Modell.</source><year>2006</year><volume>25</volume><issue>2</issue><fpage>247</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.jmgm.2005.12.005</pub-id><pub-id pub-id-type="pmid">16458552</pub-id></element-citation></ref><ref id="ref86"><element-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Tian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kasavajhala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Belfon</surname><given-names>K. A. A.</given-names></name><name name-style="western"><surname>Raguette</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Migues</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Bickel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pincay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Simmerling</surname><given-names>C.</given-names></name><article-title>ff19SB: Amino-Acid-Specific Protein Backbone Parameters
Trained against Quantum Mechanics Energy Surfaces in Solution</article-title><source>J. Chem. Theory Comput</source><year>2020</year><volume>16</volume><issue>1</issue><fpage>528</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.9b00591</pub-id><pub-id pub-id-type="pmid">31714766</pub-id></element-citation></ref><ref id="ref87"><element-citation publication-type="journal" id="cit87"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name><article-title>Development
and testing of a general amber force field</article-title><source>J. Comput. Chem.</source><year>2004</year><volume>25</volume><issue>9</issue><fpage>1157</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1002/jcc.20035</pub-id><pub-id pub-id-type="pmid">15116359</pub-id></element-citation></ref><ref id="ref88"><element-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Roe</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Cheatham</surname><given-names>T. E.</given-names><suffix>3rd.</suffix></name><article-title>PTRAJ and CPPTRAJ: Software for Processing
and Analysis of Molecular Dynamics Trajectory Data</article-title><source>J. Chem. Theory Comput</source><year>2013</year><volume>9</volume><issue>7</issue><fpage>3084</fpage><lpage>3095</lpage><pub-id pub-id-type="doi">10.1021/ct400341p</pub-id><pub-id pub-id-type="pmid">26583988</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>